Someday personal page - To The Moon

Someday

Someday

No personal profile

255Follow

7Followers

0Topic

0Badge

2023-12-21

Great ariticle, would you like to share it?

@TigerEvents:🐅🌟 TIGER TYCOON CHALLENGE IS ON! 🌟🐅

2021-12-27

go

3 Biotech Stocks That Sank in 2021 but Could Soar in 2022

2021-08-25

Good

Eyewear maker Warby Parker to go public via direct listing on NYSE

2021-06-21

Go

Next Market Crash: 2 Top Growth Stocks to Buy Right Now

2021-06-17

Go

Fisker Jumps on EV-Production Pact With Magna International

2021-04-27

Good

Microsoft Nears $2 Trillion Market Cap. Earnings Are Tuesday.

2021-04-26

Good!

TSMC will invest $ 2.8 billion in China in order to increase chip production car

2021-04-24

Hmmmm

‘Black Swan’ author calls bitcoin a ‘gimmick’ and a ‘game,’ says it resembles a Ponzi scheme

2021-04-18

Zzzz

Hedge Fund Billionaire Who Shorted Lehman Brothers Says the Fed and SEC Aren’t Doing Their Jobs

2021-04-16

goooooo

DraftKings, Caesars and FanDuel ready for action after historic NFL sports betting deal

2021-04-14

Goooo

Import/Export Prices Explode Higher In March, Hottest In A Decade

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3567913702226999","uuid":"3567913702226999","gmtCreate":1611582182578,"gmtModify":1679936550754,"name":"Someday","pinyin":"someday","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":255,"tweetSize":23,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.09%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":254449493717208,"gmtCreate":1703158233468,"gmtModify":1703158236547,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/254449493717208","repostId":"248312805347464","repostType":1,"repost":{"id":248312805347464,"gmtCreate":1701660745864,"gmtModify":1703059991513,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"🐅🌟 TIGER TYCOON CHALLENGE IS ON! 🌟🐅","htmlText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","listText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","text":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct & Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/248312805347464","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009143889,"gmtCreate":1640579576165,"gmtModify":1676533527250,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"go","listText":"go","text":"go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009143889","repostId":"2194177136","repostType":4,"repost":{"id":"2194177136","pubTimestamp":1640572338,"share":"https://ttm.financial/m/news/2194177136?lang=&edition=fundamental","pubTime":"2021-12-27 10:32","market":"us","language":"en","title":"3 Biotech Stocks That Sank in 2021 but Could Soar in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2194177136","media":"Motley Fool","summary":"These stocks could rebound nicely in the new year.","content":"<p>There's no denying that 2021 has been a rough year for many biotech stocks. The shares of quite a few big and small biotech companies alike are set to finish the year in negative territory. But those disappointing performances won't necessarily extend into the future.</p>\n<p>We asked three Motley Fool contributors to pick biotech stocks that sank in 2021 but could soar in 2022. Here's why they chose <a href=\"https://laohu8.com/S/AXSM\"><b>Axsome Therapeutics</b> </a>, <a href=\"https://laohu8.com/S/NVS\"><b>Novartis</b> </a>, and <a href=\"https://laohu8.com/S/VRTX\"><b>Vertex Pharmaceuticals</b> </a>.</p>\n<h2>Long-term catalysts abound for this biotech</h2>\n<p><b>Prosper Junior Bakiny (Axsome Therapeutics):</b> Shares of Axsome Therapeutics have dropped by more than 50% this year. The company has had to deal with various setbacks. Most notably, the regulatory review of Axsome Therapeutics' lead pipeline candidate, AXS-05, was delayed. The Food and Drug Administration (FDA) was supposed to complete its review of the potential therapy for major depressive disorder in late August.</p>\n<p>But the agency found deficiencies in Axsome Therapeutics' application. As a result, the FDA has yet to approve the drug. While this issue hurt Axsome Therapeutics' stock performance, the future looks bright for the company. AXS-05 proved effective at reducing the symptoms of depression in a late-stage study.</p>\n<p>The need for a medicine like AXS-05 has only increased as a result of the pandemic, with the number of people suffering from symptoms of depression nearly quadrupling to 80 million since the outbreak started. AXS-05's delayed review isn't ideal, to say the least. But given the solid results it delivered in clinical trials and the dire need for depression therapies, it looks likely to hit the market eventually.</p>\n<p>But Axsome Therapeutics is also developing several other medicines. These include AXS-07, a potential treatment for migraines, and AXS-12 and AXS-14, aimed at treating narcolepsy and fibromyalgia, respectively. The company estimates the potential annual sales of these medicines to be between $4 billion and $9 billion.</p>\n<p>Meanwhile, Axsome Therapeutics' market cap of $1.4 billion is currently less than half of the low end of these projections. That gives Axsome Therapeutics a tremendous upside potential. Naturally, risks are involved; the company could run into more regulatory roadblocks for AXS-05 or some other pipeline candidate.</p>\n<p>But on the flip side, if Axsome Therapeutics starts racking up regulatory approvals for its therapies, its shares will soar next year and beyond. While I wouldn't recommend going all-in on this company -- it'd be best to initiate a small position, for now -- 2022 could prove to be a much better year for the biotech.</p>\n<h2>Ready to take off</h2>\n<p><b>David Jagielski</b>&nbsp;<b>(Novartis):&nbsp;</b>Investors have been moving away from high-priced growth stocks and into more value-oriented investments in recent weeks. One stock that has benefited from that is healthcare company Novartis, which is up over 5% in the past month while the <b>S&amp;P 500</b> has fallen 2%. The drugmaker's shares are still down 9% year to date. But if the shift to value stocks continues, Novartis may continue climbing into next year.</p>\n<p>The business itself is in solid shape. Novartis posted a profit of $9.8 billion on sales of $52.4 billion over the trailing 12 months, good for a profit margin of just under 19%. It has also generated a boatload of money, with free cash flow during that time coming in at $12.2 billion. And the company is getting even more cash into its financials after selling its stake in drugmaker <b>Roche</b>&nbsp;for $20.7 billion. As a result of this windfall of cash, the company is planning to buy back up to $15 billion worth of its shares by the end of 2023.</p>\n<p>Cash is king, and Novartis is generating plenty of it these days. That will give the company lots of flexibility moving forward should it want to pursue an acquisition or invest in expanding its business in other ways. Novartis projects that through new products and approvals its business can continue growing sales by at least 4% per year until 2026.</p>\n<p>Currently, the stock trades at 20 times earnings. That's a deal given that the average healthcare stock in the <b>Health Care Select Sector SPDR Fund</b>&nbsp;trades at a multiple of more than 25. And Novartis' dividend yield of 3.8% makes the stock even more attractive to long-term investors. The average stock on the S&amp;P 500 pays a dividend that yields only 1.3%. I'm confident that as investors focus more on value next year, Novartis could become a more popular stock to own.</p>\n<h2>This monopoly is playing some new games</h2>\n<p><b>Keith Speights (Vertex Pharmaceuticals):</b> Vertex's share price dropped close to 25% year to date by early October. The biotech stock has since made a solid comeback, but it's still down 6%.</p>\n<p>The company has enjoyed a virtual monopoly in treating the underlying cause of cystic fibrosis (CF) for years. Vertex still has growth potential in the global CF market. However, investors have been anxious for the drugmaker to successfully expand into new therapeutic areas. Although Vertex has experienced some failures in the past with these efforts, it appears to be in a strong position to branch out beyond CF now.</p>\n<p>Vertex and <b>CRISPR Therapeutics</b> expect to file for regulatory approvals of CTX001 in late 2022. CTX001 is a promising CRISPR gene-editing therapy that could effectively cure transfusion-dependent beta-thalassemia and sickle cell disease.</p>\n<p>In addition to this partnered program, Vertex is advancing its internally developed candidate VX-147 into pivotal studies early next year targeting APOL1-mediated kidney disease. The company reported positive results from a phase 2 study evaluating the experimental drug earlier this month. Over 100,000 people in the U.S. and Europe have APOL1-mediated kidney disease. That's a bigger market than CF for Vertex to target.</p>\n<p>CTX001, VX-147, and continued momentum for the CF franchise are likely to be the primary growth drivers for Vertex in the near term. Over the longer term, though, the company could have additional winners from its pipeline. Vertex also has a hefty cash stockpile to use in making acquisitions and licensing deals.</p>\n<p>This has been a disappointing year for the big biotech stock. But&nbsp;I think 2022 will be a happy new year for Vertex shareholders.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks That Sank in 2021 but Could Soar in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks That Sank in 2021 but Could Soar in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 10:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/26/3-biotech-stocks-that-sank-in-2021-but-could-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no denying that 2021 has been a rough year for many biotech stocks. The shares of quite a few big and small biotech companies alike are set to finish the year in negative territory. But those ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/26/3-biotech-stocks-that-sank-in-2021-but-could-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc.","BK4567":"ESG概念","CF":"CF工业","BK4532":"文艺复兴科技持仓","BK4505":"高瓴资本持仓","NVS":"诺华","VERX":"Vertex, Inc.","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","VRTX":"福泰制药","BK4023":"应用软件","BK4007":"制药","BK4093":"化肥与农用药剂"},"source_url":"https://www.fool.com/investing/2021/12/26/3-biotech-stocks-that-sank-in-2021-but-could-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194177136","content_text":"There's no denying that 2021 has been a rough year for many biotech stocks. The shares of quite a few big and small biotech companies alike are set to finish the year in negative territory. But those disappointing performances won't necessarily extend into the future.\nWe asked three Motley Fool contributors to pick biotech stocks that sank in 2021 but could soar in 2022. Here's why they chose Axsome Therapeutics , Novartis , and Vertex Pharmaceuticals .\nLong-term catalysts abound for this biotech\nProsper Junior Bakiny (Axsome Therapeutics): Shares of Axsome Therapeutics have dropped by more than 50% this year. The company has had to deal with various setbacks. Most notably, the regulatory review of Axsome Therapeutics' lead pipeline candidate, AXS-05, was delayed. The Food and Drug Administration (FDA) was supposed to complete its review of the potential therapy for major depressive disorder in late August.\nBut the agency found deficiencies in Axsome Therapeutics' application. As a result, the FDA has yet to approve the drug. While this issue hurt Axsome Therapeutics' stock performance, the future looks bright for the company. AXS-05 proved effective at reducing the symptoms of depression in a late-stage study.\nThe need for a medicine like AXS-05 has only increased as a result of the pandemic, with the number of people suffering from symptoms of depression nearly quadrupling to 80 million since the outbreak started. AXS-05's delayed review isn't ideal, to say the least. But given the solid results it delivered in clinical trials and the dire need for depression therapies, it looks likely to hit the market eventually.\nBut Axsome Therapeutics is also developing several other medicines. These include AXS-07, a potential treatment for migraines, and AXS-12 and AXS-14, aimed at treating narcolepsy and fibromyalgia, respectively. The company estimates the potential annual sales of these medicines to be between $4 billion and $9 billion.\nMeanwhile, Axsome Therapeutics' market cap of $1.4 billion is currently less than half of the low end of these projections. That gives Axsome Therapeutics a tremendous upside potential. Naturally, risks are involved; the company could run into more regulatory roadblocks for AXS-05 or some other pipeline candidate.\nBut on the flip side, if Axsome Therapeutics starts racking up regulatory approvals for its therapies, its shares will soar next year and beyond. While I wouldn't recommend going all-in on this company -- it'd be best to initiate a small position, for now -- 2022 could prove to be a much better year for the biotech.\nReady to take off\nDavid Jagielski (Novartis): Investors have been moving away from high-priced growth stocks and into more value-oriented investments in recent weeks. One stock that has benefited from that is healthcare company Novartis, which is up over 5% in the past month while the S&P 500 has fallen 2%. The drugmaker's shares are still down 9% year to date. But if the shift to value stocks continues, Novartis may continue climbing into next year.\nThe business itself is in solid shape. Novartis posted a profit of $9.8 billion on sales of $52.4 billion over the trailing 12 months, good for a profit margin of just under 19%. It has also generated a boatload of money, with free cash flow during that time coming in at $12.2 billion. And the company is getting even more cash into its financials after selling its stake in drugmaker Roche for $20.7 billion. As a result of this windfall of cash, the company is planning to buy back up to $15 billion worth of its shares by the end of 2023.\nCash is king, and Novartis is generating plenty of it these days. That will give the company lots of flexibility moving forward should it want to pursue an acquisition or invest in expanding its business in other ways. Novartis projects that through new products and approvals its business can continue growing sales by at least 4% per year until 2026.\nCurrently, the stock trades at 20 times earnings. That's a deal given that the average healthcare stock in the Health Care Select Sector SPDR Fund trades at a multiple of more than 25. And Novartis' dividend yield of 3.8% makes the stock even more attractive to long-term investors. The average stock on the S&P 500 pays a dividend that yields only 1.3%. I'm confident that as investors focus more on value next year, Novartis could become a more popular stock to own.\nThis monopoly is playing some new games\nKeith Speights (Vertex Pharmaceuticals): Vertex's share price dropped close to 25% year to date by early October. The biotech stock has since made a solid comeback, but it's still down 6%.\nThe company has enjoyed a virtual monopoly in treating the underlying cause of cystic fibrosis (CF) for years. Vertex still has growth potential in the global CF market. However, investors have been anxious for the drugmaker to successfully expand into new therapeutic areas. Although Vertex has experienced some failures in the past with these efforts, it appears to be in a strong position to branch out beyond CF now.\nVertex and CRISPR Therapeutics expect to file for regulatory approvals of CTX001 in late 2022. CTX001 is a promising CRISPR gene-editing therapy that could effectively cure transfusion-dependent beta-thalassemia and sickle cell disease.\nIn addition to this partnered program, Vertex is advancing its internally developed candidate VX-147 into pivotal studies early next year targeting APOL1-mediated kidney disease. The company reported positive results from a phase 2 study evaluating the experimental drug earlier this month. Over 100,000 people in the U.S. and Europe have APOL1-mediated kidney disease. That's a bigger market than CF for Vertex to target.\nCTX001, VX-147, and continued momentum for the CF franchise are likely to be the primary growth drivers for Vertex in the near term. Over the longer term, though, the company could have additional winners from its pipeline. Vertex also has a hefty cash stockpile to use in making acquisitions and licensing deals.\nThis has been a disappointing year for the big biotech stock. But I think 2022 will be a happy new year for Vertex shareholders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837054593,"gmtCreate":1629849811712,"gmtModify":1676530148776,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/837054593","repostId":"2162608721","repostType":4,"repost":{"id":"2162608721","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629847834,"share":"https://ttm.financial/m/news/2162608721?lang=&edition=fundamental","pubTime":"2021-08-25 07:30","market":"us","language":"en","title":"Eyewear maker Warby Parker to go public via direct listing on NYSE","url":"https://stock-news.laohu8.com/highlight/detail?id=2162608721","media":"Reuters","summary":"Aug 24 (Reuters) - Eyewear company Warby Parker on Tuesday filed paperwork with U.S. regulators for ","content":"<p>Aug 24 (Reuters) - Eyewear company Warby Parker on Tuesday filed paperwork with U.S. regulators for a direct listing on the New York Stock Exchange, revealing a 53% surge in revenue for the first half of 2021.</p>\n<p>The company, whose existing investors include Tiger Global Management and General Catalyst, did not disclose the number of Class A common shares its stockholders were looking to sell. It will not receive any proceeds from the sale of such shares.</p>\n<p>The New York-based firm, known for its fashionable eyewear starting at $95, was valued at $3 billion after a $245 million funding round in 2020, the Wall Street Journal had reported</p>\n<p>The co-founders of Warby, who were classmates at the Wharton School of the University of Pennsylvania, got the idea for the company in 2008 after co-Chief Executive Officer Dave Gilboa found the cost of replacing eyeglasses lost on a Southeast Asia backpacking trip to be too high.</p>\n<p>Founded later in 2010, the company now has an active consumer base that exceeds two million as rising usage of smartphones, tablets and other devices increases the need for vision correction.</p>\n<p>A direct listing like Warby's allows companies to list their stock on public exchanges by sidestepping a costly and time-consuming initial public offering.</p>\n<p>The U.S. Securities and Exchange Commission approved a Nasdaq Inc&nbsp;proposal to allow companies to raise capital through direct listings in May. Companies have not raised any capital through such listing procedures so far.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eyewear maker Warby Parker to go public via direct listing on NYSE</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyewear maker Warby Parker to go public via direct listing on NYSE\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-25 07:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 24 (Reuters) - Eyewear company Warby Parker on Tuesday filed paperwork with U.S. regulators for a direct listing on the New York Stock Exchange, revealing a 53% surge in revenue for the first half of 2021.</p>\n<p>The company, whose existing investors include Tiger Global Management and General Catalyst, did not disclose the number of Class A common shares its stockholders were looking to sell. It will not receive any proceeds from the sale of such shares.</p>\n<p>The New York-based firm, known for its fashionable eyewear starting at $95, was valued at $3 billion after a $245 million funding round in 2020, the Wall Street Journal had reported</p>\n<p>The co-founders of Warby, who were classmates at the Wharton School of the University of Pennsylvania, got the idea for the company in 2008 after co-Chief Executive Officer Dave Gilboa found the cost of replacing eyeglasses lost on a Southeast Asia backpacking trip to be too high.</p>\n<p>Founded later in 2010, the company now has an active consumer base that exceeds two million as rising usage of smartphones, tablets and other devices increases the need for vision correction.</p>\n<p>A direct listing like Warby's allows companies to list their stock on public exchanges by sidestepping a costly and time-consuming initial public offering.</p>\n<p>The U.S. Securities and Exchange Commission approved a Nasdaq Inc&nbsp;proposal to allow companies to raise capital through direct listings in May. Companies have not raised any capital through such listing procedures so far.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162608721","content_text":"Aug 24 (Reuters) - Eyewear company Warby Parker on Tuesday filed paperwork with U.S. regulators for a direct listing on the New York Stock Exchange, revealing a 53% surge in revenue for the first half of 2021.\nThe company, whose existing investors include Tiger Global Management and General Catalyst, did not disclose the number of Class A common shares its stockholders were looking to sell. It will not receive any proceeds from the sale of such shares.\nThe New York-based firm, known for its fashionable eyewear starting at $95, was valued at $3 billion after a $245 million funding round in 2020, the Wall Street Journal had reported\nThe co-founders of Warby, who were classmates at the Wharton School of the University of Pennsylvania, got the idea for the company in 2008 after co-Chief Executive Officer Dave Gilboa found the cost of replacing eyeglasses lost on a Southeast Asia backpacking trip to be too high.\nFounded later in 2010, the company now has an active consumer base that exceeds two million as rising usage of smartphones, tablets and other devices increases the need for vision correction.\nA direct listing like Warby's allows companies to list their stock on public exchanges by sidestepping a costly and time-consuming initial public offering.\nThe U.S. Securities and Exchange Commission approved a Nasdaq Inc proposal to allow companies to raise capital through direct listings in May. Companies have not raised any capital through such listing procedures so far.","news_type":1},"isVote":1,"tweetType":1,"viewCount":446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164261351,"gmtCreate":1624208729873,"gmtModify":1703830685161,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Go","listText":"Go","text":"Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164261351","repostId":"2144775875","repostType":4,"repost":{"id":"2144775875","pubTimestamp":1624024260,"share":"https://ttm.financial/m/news/2144775875?lang=&edition=fundamental","pubTime":"2021-06-18 21:51","market":"us","language":"en","title":"Next Market Crash: 2 Top Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2144775875","media":"Motley Fool","summary":"Don't wait to jump on this red-hot tech company and unstoppable dividend stock.","content":"<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.</p>\n<p>No matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.</p>\n<h2>1. <a href=\"https://laohu8.com/S/FB\">Facebook</a></h2>\n<p><b>Facebook</b> (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.</p>\n<p>Facebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.</p>\n<p>2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.</p>\n<p>Facebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.</p>\n<p>If you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.</p>\n<p>After nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, <a href=\"https://laohu8.com/S/AONE\">one</a> that can generate consistent growth and maximize your portfolio returns.</p>\n<h2>2. AbbVie</h2>\n<p>Healthcare stock <b>AbbVie</b> (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from <b>Abbott Laboratories </b>in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.</p>\n<p>Stocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.</p>\n<p>The biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.</p>\n<p>There's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.</p>\n<p>Case in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.</p>\n<p>It's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.</p>\n<p>AbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.</p>\n<p>If you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Next Market Crash: 2 Top Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNext Market Crash: 2 Top Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144775875","content_text":"The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.\nNo matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.\n1. Facebook\nFacebook (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.\nFacebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.\n2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.\nFacebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.\nIf you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.\nAfter nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, one that can generate consistent growth and maximize your portfolio returns.\n2. AbbVie\nHealthcare stock AbbVie (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from Abbott Laboratories in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.\nStocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.\nThe biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.\nThere's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.\nCase in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.\nIt's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.\nAbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.\nIf you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.","news_type":1},"isVote":1,"tweetType":1,"viewCount":524,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161774535,"gmtCreate":1623942304627,"gmtModify":1703824222248,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Go","listText":"Go","text":"Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161774535","repostId":"1175322624","repostType":4,"repost":{"id":"1175322624","pubTimestamp":1623940991,"share":"https://ttm.financial/m/news/1175322624?lang=&edition=fundamental","pubTime":"2021-06-17 22:43","market":"us","language":"en","title":"Fisker Jumps on EV-Production Pact With Magna International","url":"https://stock-news.laohu8.com/highlight/detail?id=1175322624","media":".thestreet","summary":"Fisker   was higher after it said it signed an agreement under which Magna International,  the mobility technology company, would produce its electric vehicles.As part of the partnership, Fisker's all-electric Ocean SUV is expected to start production at the Aurora, Ontario, company's facility in Graz, Austria, starting Nov. 17, 2022.\"From the start of this partnership, Fisker and Magna aligned very quickly on the importance of delivering a high-quality vehicle on time,\" Chief Executive Henrik F","content":"<p>Fisker&nbsp;(<b>FSR</b>) &nbsp;was higher after it&nbsp;said&nbsp;it signed an agreement under which Magna International,&nbsp;(<b>MGA</b>)&nbsp;the mobility technology company, would produce its electric vehicles.</p>\n<p>As part of the partnership, Fisker's all-electric Ocean SUV is expected to start production at the Aurora, Ontario, company's facility in Graz, Austria, starting Nov. 17, 2022.</p>\n<p>\"From the start of this partnership, Fisker and Magna aligned very quickly on the importance of delivering a high-quality vehicle on time,\" Chief Executive Henrik Fisker said in a statement.</p>\n<p>The Graz manufacturing facility has produced more than 3.7 million vehicles for several global automakers.</p>\n<p>The agreement is \"broad-based\" covering planned volumes, manufacturing costs and quality metrics over the program's lifecycle which runs through 2029.</p>\n<p>The Ocean SUV from the Los Angeles company will use a version of a Magna-developed electric-vehicle architecture. Fisker will modify that architecture to create new intellectual property that it expects to deliver \"class-leading range\" while also lowering manufacturing costs.</p>\n<p>Fisker now expects Ocean to enter the market with a starting list price of $37,499 in the U.S., excluding electric vehicle-related subsidies, and below&nbsp;€32,000 ($38,200) in Germany (including taxes and EV-related subsidies).</p>\n<p>\"Our asset-lite model, reinforced by partners like Magna, is powering Fisker towards its planned delivery of the Ocean with features and functions exceeding our original aspirations,\" said Fisker. He added that the company is scaling rapidly.</p>\n<p>Fisker shares at last check were 3.1% higher at $18.29. Magna's shares traded on the New York Stock Exchange were off 0.5% at $92.74.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fisker Jumps on EV-Production Pact With Magna International</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFisker Jumps on EV-Production Pact With Magna International\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/fisker-higher-after-finalizing-magna-intl-production-agreement><strong>.thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fisker (FSR)  was higher after it said it signed an agreement under which Magna International, (MGA) the mobility technology company, would produce its electric vehicles.\nAs part of the partnership, ...</p>\n\n<a href=\"https://www.thestreet.com/investing/fisker-higher-after-finalizing-magna-intl-production-agreement\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSR":"菲斯克"},"source_url":"https://www.thestreet.com/investing/fisker-higher-after-finalizing-magna-intl-production-agreement","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175322624","content_text":"Fisker (FSR)  was higher after it said it signed an agreement under which Magna International, (MGA) the mobility technology company, would produce its electric vehicles.\nAs part of the partnership, Fisker's all-electric Ocean SUV is expected to start production at the Aurora, Ontario, company's facility in Graz, Austria, starting Nov. 17, 2022.\n\"From the start of this partnership, Fisker and Magna aligned very quickly on the importance of delivering a high-quality vehicle on time,\" Chief Executive Henrik Fisker said in a statement.\nThe Graz manufacturing facility has produced more than 3.7 million vehicles for several global automakers.\nThe agreement is \"broad-based\" covering planned volumes, manufacturing costs and quality metrics over the program's lifecycle which runs through 2029.\nThe Ocean SUV from the Los Angeles company will use a version of a Magna-developed electric-vehicle architecture. Fisker will modify that architecture to create new intellectual property that it expects to deliver \"class-leading range\" while also lowering manufacturing costs.\nFisker now expects Ocean to enter the market with a starting list price of $37,499 in the U.S., excluding electric vehicle-related subsidies, and below €32,000 ($38,200) in Germany (including taxes and EV-related subsidies).\n\"Our asset-lite model, reinforced by partners like Magna, is powering Fisker towards its planned delivery of the Ocean with features and functions exceeding our original aspirations,\" said Fisker. He added that the company is scaling rapidly.\nFisker shares at last check were 3.1% higher at $18.29. Magna's shares traded on the New York Stock Exchange were off 0.5% at $92.74.","news_type":1},"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377216529,"gmtCreate":1619530397761,"gmtModify":1704725481664,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/377216529","repostId":"1155157199","repostType":4,"repost":{"id":"1155157199","pubTimestamp":1619494851,"share":"https://ttm.financial/m/news/1155157199?lang=&edition=fundamental","pubTime":"2021-04-27 11:40","market":"us","language":"en","title":"Microsoft Nears $2 Trillion Market Cap. Earnings Are Tuesday.","url":"https://stock-news.laohu8.com/highlight/detail?id=1155157199","media":"Barrons","summary":"Wall Street is expecting Microsoft to report strong financial results when the company posts its March quarter numbers after the close of trading on Tuesday.The consensus forecast among analysts is for revenue of $41 billion, up 17% from a year ago, with profits of $1.78 a share.  On Monday, Microsoft stock set an intraday record of $262.44, leaving the stock just a modest rally away from hitting a $2 trillion valuation for the first time. To get there, the stock needs to rise to $264.55.J.P. Mo","content":"<p>Wall Street is expecting Microsoft to report strong financial results when the company posts its March quarter numbers after the close of trading on Tuesday.</p><p>The consensus forecast among analysts is for revenue of $41 billion, up 17% from a year ago, with profits of $1.78 a share.&nbsp; On Monday, Microsoft stock set an intraday record of $262.44, leaving the stock just a modest rally away from hitting a $2 trillion valuation for the first time. To get there, the stock needs to rise to $264.55.</p><p>The shares have gained 18% year to date.</p><p>Analysts expect another strong quarter from the company’s Azure and Office 365 cloud businesses, and will be looking for signs of accelerating growth in its enterprise operation. Sales of Surface hardware—laptops and whiteboards—were likely strong in the quarter, given the huge recent growth in PC purchases, although there is some potential that shortages of components resulted in unfilled demand. Strength in the PC market also bodes well for sales of the Windows operating system.&nbsp;</p><p>Microsoft breaks down its results into&nbsp;three segments: Productivity and Business Processes, which includes Office 365, Dynamics, and LinkedIn; Intelligence Cloud, which includes Azure and enterprise server software; and More Personal Computing, which includes Windows, Xbox, Surface hardware, and Bing.</p><p>When Microsoft reported its results for its fiscal second quarter in late January,CFO Amy Hood provided revenue guidance for each segment. For Productivity and Business Processes, she projected revenue of $13.35 billion to $13.6 billion. The call for Intelligent Cloud was for revenue of $14.7 billion to $14.95 billion, while she predicted $12.3 billion to $12.7 billion for More Personal Computing. If revenue for each segment came in at the top of its forecast range, the total would be $41.25 billion.</p><p>In research notes, several analysts cited positive comments from customers and resellers in projecting strong results.</p><p>Last week, KeyBanc Capital’s Michael Turits repeated his Overweight rating on the stock while lifting his target for the price to $295, from $280. He says the company is likely benefiting from a combination of strong IT demand and continuing strength in PC shipments.</p><p>“We continue to see Microsoft’s combination of expanding Azure scope, broad enterprise application innovation, and aggressive bundling seeing success in the market,” he wrote. “Nearly all North American Microsoft distributors/resellers we spoke with reported Microsoft channel revenue on or above plan.”</p><p>J.P. Morgan analyst Mark Murphy came away from his own new survey of resellers of Microsoft products encouraged about the outlook. He says those companies’ quarterly sales of Microsoft goods came in an average of 3.3% above their expectations, driven by improving enterprise demand. He reported strength across the company’s enterprise product lines, with growth in Azure, Teams, Office 365, and security products, among other places. Murphy rates Microsoft at Overweight and has a target of $245 for the stock price.</p><p>Wedbush analyst Dan Ives&nbsp;forecast “another masterpiece quarter,” driven by growth of at least 45% from Azure, which he thinks is taking market share from Amazon Web Services. He said the current work-from-home environment is encouraging more businesses to make strategic moves toward cloud-based operations “with Microsoft across the board with Azure growth remaining brisk.” He maintained an Outperform rating, with a target of $300 for the share price.</p><p>Citi analyst Tyler Radke&nbsp;last week reiterated a Buy rating on Microsoft shares, lifting his price target to $302, from $292, and setting a “positive catalyst watch” on the stock ahead of the results. He wrote that a combination of a survey of resellers and channel checks made him more confident that Microsoft can propel revenue across all three primary business segments, with strength in personal computer demand from both consumers and businesses, robust upgrade activity on server software, and continued strength in Azure as a result of “continued strong enterprise consumption growth.”&nbsp;</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft Nears $2 Trillion Market Cap. Earnings Are Tuesday.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft Nears $2 Trillion Market Cap. Earnings Are Tuesday.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/microsoft-nears-2-trillion-market-cap-earnings-are-tuesday-51619457928?mod=hp_DAY_Theme_2_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street is expecting Microsoft to report strong financial results when the company posts its March quarter numbers after the close of trading on Tuesday.The consensus forecast among analysts is ...</p>\n\n<a href=\"https://www.barrons.com/articles/microsoft-nears-2-trillion-market-cap-earnings-are-tuesday-51619457928?mod=hp_DAY_Theme_2_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://www.barrons.com/articles/microsoft-nears-2-trillion-market-cap-earnings-are-tuesday-51619457928?mod=hp_DAY_Theme_2_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155157199","content_text":"Wall Street is expecting Microsoft to report strong financial results when the company posts its March quarter numbers after the close of trading on Tuesday.The consensus forecast among analysts is for revenue of $41 billion, up 17% from a year ago, with profits of $1.78 a share.  On Monday, Microsoft stock set an intraday record of $262.44, leaving the stock just a modest rally away from hitting a $2 trillion valuation for the first time. To get there, the stock needs to rise to $264.55.The shares have gained 18% year to date.Analysts expect another strong quarter from the company’s Azure and Office 365 cloud businesses, and will be looking for signs of accelerating growth in its enterprise operation. Sales of Surface hardware—laptops and whiteboards—were likely strong in the quarter, given the huge recent growth in PC purchases, although there is some potential that shortages of components resulted in unfilled demand. Strength in the PC market also bodes well for sales of the Windows operating system. Microsoft breaks down its results into three segments: Productivity and Business Processes, which includes Office 365, Dynamics, and LinkedIn; Intelligence Cloud, which includes Azure and enterprise server software; and More Personal Computing, which includes Windows, Xbox, Surface hardware, and Bing.When Microsoft reported its results for its fiscal second quarter in late January,CFO Amy Hood provided revenue guidance for each segment. For Productivity and Business Processes, she projected revenue of $13.35 billion to $13.6 billion. The call for Intelligent Cloud was for revenue of $14.7 billion to $14.95 billion, while she predicted $12.3 billion to $12.7 billion for More Personal Computing. If revenue for each segment came in at the top of its forecast range, the total would be $41.25 billion.In research notes, several analysts cited positive comments from customers and resellers in projecting strong results.Last week, KeyBanc Capital’s Michael Turits repeated his Overweight rating on the stock while lifting his target for the price to $295, from $280. He says the company is likely benefiting from a combination of strong IT demand and continuing strength in PC shipments.“We continue to see Microsoft’s combination of expanding Azure scope, broad enterprise application innovation, and aggressive bundling seeing success in the market,” he wrote. “Nearly all North American Microsoft distributors/resellers we spoke with reported Microsoft channel revenue on or above plan.”J.P. Morgan analyst Mark Murphy came away from his own new survey of resellers of Microsoft products encouraged about the outlook. He says those companies’ quarterly sales of Microsoft goods came in an average of 3.3% above their expectations, driven by improving enterprise demand. He reported strength across the company’s enterprise product lines, with growth in Azure, Teams, Office 365, and security products, among other places. Murphy rates Microsoft at Overweight and has a target of $245 for the stock price.Wedbush analyst Dan Ives forecast “another masterpiece quarter,” driven by growth of at least 45% from Azure, which he thinks is taking market share from Amazon Web Services. He said the current work-from-home environment is encouraging more businesses to make strategic moves toward cloud-based operations “with Microsoft across the board with Azure growth remaining brisk.” He maintained an Outperform rating, with a target of $300 for the share price.Citi analyst Tyler Radke last week reiterated a Buy rating on Microsoft shares, lifting his price target to $302, from $292, and setting a “positive catalyst watch” on the stock ahead of the results. He wrote that a combination of a survey of resellers and channel checks made him more confident that Microsoft can propel revenue across all three primary business segments, with strength in personal computer demand from both consumers and businesses, robust upgrade activity on server software, and continued strength in Azure as a result of “continued strong enterprise consumption growth.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374695247,"gmtCreate":1619443163689,"gmtModify":1704723930695,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/374695247","repostId":"1186896771","repostType":2,"repost":{"id":"1186896771","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619442925,"share":"https://ttm.financial/m/news/1186896771?lang=&edition=fundamental","pubTime":"2021-04-26 21:15","market":"us","language":"en","title":"TSMC will invest $ 2.8 billion in China in order to increase chip production car","url":"https://stock-news.laohu8.com/highlight/detail?id=1186896771","media":"Tiger Newspress","summary":"TSMC will invest $ 2.8 billion in China in order to increase chip production car.","content":"<p>TSMC will invest $ 2.8 billion in China in order to increase chip production car.</p>\n<p><img src=\"https://static.tigerbbs.com/316b416c90dad568e492750f39e0aa30\" tg-width=\"840\" tg-height=\"470\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TSMC will invest $ 2.8 billion in China in order to increase chip production car</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTSMC will invest $ 2.8 billion in China in order to increase chip production car\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-26 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TSMC will invest $ 2.8 billion in China in order to increase chip production car.</p>\n<p><img src=\"https://static.tigerbbs.com/316b416c90dad568e492750f39e0aa30\" tg-width=\"840\" tg-height=\"470\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSM":"台积电"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186896771","content_text":"TSMC will invest $ 2.8 billion in China in order to increase chip production car.","news_type":1},"isVote":1,"tweetType":1,"viewCount":436,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375916271,"gmtCreate":1619275670193,"gmtModify":1704722042733,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375916271","repostId":"1179843002","repostType":4,"repost":{"id":"1179843002","pubTimestamp":1619190162,"share":"https://ttm.financial/m/news/1179843002?lang=&edition=fundamental","pubTime":"2021-04-23 23:02","market":"fut","language":"en","title":"‘Black Swan’ author calls bitcoin a ‘gimmick’ and a ‘game,’ says it resembles a Ponzi scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1179843002","media":"CNBC","summary":"KEY POINTS\n\n“Black Swan” author Nassim Taleb ripped bitcoin as a “gimmick” that’s too volatile to be","content":"<div>\n<p>KEY POINTS\n\n“Black Swan” author Nassim Taleb ripped bitcoin as a “gimmick” that’s too volatile to be a currency and an unsafe hedge against inflation.\n“Basically, there’s no connection between ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/23/bitcoin-a-gimmick-and-resembles-a-ponzi-scheme-black-swan-author-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>‘Black Swan’ author calls bitcoin a ‘gimmick’ and a ‘game,’ says it resembles a Ponzi scheme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n‘Black Swan’ author calls bitcoin a ‘gimmick’ and a ‘game,’ says it resembles a Ponzi scheme\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/23/bitcoin-a-gimmick-and-resembles-a-ponzi-scheme-black-swan-author-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\n“Black Swan” author Nassim Taleb ripped bitcoin as a “gimmick” that’s too volatile to be a currency and an unsafe hedge against inflation.\n“Basically, there’s no connection between ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/23/bitcoin-a-gimmick-and-resembles-a-ponzi-scheme-black-swan-author-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust","SQ":"Block","PYPL":"PayPal","TSLA":"特斯拉"},"source_url":"https://www.cnbc.com/2021/04/23/bitcoin-a-gimmick-and-resembles-a-ponzi-scheme-black-swan-author-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1179843002","content_text":"KEY POINTS\n\n“Black Swan” author Nassim Taleb ripped bitcoin as a “gimmick” that’s too volatile to be a currency and an unsafe hedge against inflation.\n“Basically, there’s no connection between inflation and bitcoin,” the former derivatives trader and current hedge fund advisor told CNBC on Friday.\nTaleb had once believed bitcoin was a promising new currency, because it was not controlled by a government. But he has since changed his mind.\n\n“Black Swan” author Nassim Taleb on Friday criticized bitcoin as a “gimmick,” telling CNBC he believes it’s too volatile to be an effective currency and it’s not a safe hedge against inflation.\n“Basically, there’s no connection between inflation and bitcoin. None. I mean, you can have hyperinflation and bitcoin going to zero. There’s no link between them,” Taleb said in a “Squawk Box” interview.\n“It’s a beautifully set up cryptographic system. It’s well made but there’s absolutely no reason it should be linked to anything economic,” added Taleb, whose bestselling 2007 book examined highly improbable events and their potential to cause severe consequences. He said bitcoin has characteristics of what he calls a Ponzi scheme that’s right out in the open.\nA Ponzi scheme is a type of fraud whereby crooks steal money from investors and mask the theft by funneling returns to clients from funds contributed by newer investors.\nTaleb had once held favorable views toward bitcoin, which was created in 2009 and is the world’s largest cryptocurrency by market value. However, he told CNBC he was “fooled by it initially” because he thought it could develop into a currency used in transactions.\n“Something that moves 5% a day, 20% in a month — up or down — cannot be a currency. It’s something else,” said Taleb, a former derivatives trader who serves as scientific advisor to hedge fund Universa Investments.\n“I bought into it ... not willing to have capital appreciation, so much as wanting to have an alternative to the fiat currency issued by central banks: A currency without a government,” Taleb said. “I realized it was not a currency without a government. It was just pure speculation. It’s just like a game ... I mean, you can create another game and call it a currency.”\nWhile some businesses do accept bitcoin as payment for goods and services, including electric vehicle maker Tesla, there are those in the crypto community who think it’s actually an asset and store of value. Bitcoin, which has its supply capped at 21 million tokens, has been described as “digital gold.”\n“It’s easily transportable and can be sent anywhere in the world if you have a smartphone so it’s a much better version, as a store of value, than gold,” famed value investor Bill Miller told CNBC earlier this week.\n“With bitcoin, volatility is the price you pay for performance,” added Miller, who has also previously contended bitcoin grows less risky as adoption and its price increases.\nIndeed, the price of bitcoin has soared higher in recent months — rising from under $11,000 per unit as recently as October to an all-time high of nearly $65,000 last week. Increased institutional adoption has been cited as one factor in its climb.\nIn keeping with its propensity for wild price swings, bitcoin has tumbled in the days since, ultimately breaking below $50,000 per token earlier Friday, a 23% drop in a little more than a week. However, the price has still risen more than 70% year to date,according to Coindesk.\nBitcoin has received long-term price targets between $400,000 and $600,000 per token from some people in the investment community, including Guggenheim Partners’Scott Minerd; others have projected even higher than that.\nTaleb suggested bitcoin’s price is not what informs his now-critical view, saying “bitcoin could go to $1 million” and it wouldn’t change his argument. “These gimmicks, you have bitcoin today. You may have another one tomorrow. They come and go, and there’s no systematic link between them and the claims they make,” he added.\nInvestors who are worried about inflation would be better off purchasing property than investing in bitcoin, Taleb said. “If you want to hedge against inflation, buy a piece of land. Grow, I don’t know, olives on it. You’ll have olive oil. If the price collapses, you’ll have something.”\n“But bitcoin, there’s no connection and, of course, the best strategy for investors is to own things that produce yields in the future. In other words, you can fall back on real dollars coming out of the company,” he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379508528,"gmtCreate":1618755946064,"gmtModify":1704714617173,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Zzzz","listText":"Zzzz","text":"Zzzz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379508528","repostId":"1131521200","repostType":4,"repost":{"id":"1131521200","pubTimestamp":1618577973,"share":"https://ttm.financial/m/news/1131521200?lang=&edition=fundamental","pubTime":"2021-04-16 20:59","market":"us","language":"en","title":"Hedge Fund Billionaire Who Shorted Lehman Brothers Says the Fed and SEC Aren’t Doing Their Jobs","url":"https://stock-news.laohu8.com/highlight/detail?id=1131521200","media":"Barron's","summary":"Stocks arehitting record highs, but not everyone is happy. Greenlight Capital’s David Einhorn is ups","content":"<p>Stocks arehitting record highs, but not everyone is happy. Greenlight Capital’s David Einhorn is upset, particularly with regulators. He has a long list of gripes, ranging from the Federal Reserve’s handling of inflation to the U.S. Securities and Exchange Commission’s lack of action on everything from Robinhood toGameStop.</p>\n<p>Einhorn’s complaints regarding the Fed are boilerplate. The Fed has the job of keeping inflation in check, but is now willing to let inflation rise above its long-term target. He doesn’t like the new laissez-faire attitude about rising prices.</p>\n<p>But Einhorn’s harshest words in a letter published Thursday were reserved for the SEC. Its job is to ensure fair trading, but Einhorn writes that it seems to have no interest in investigating spikes in the stock prices of tiny companies or statements from prominent figures such asTesla’sElon Musk and Chamath Palihapitiya that he likens to pouring “jet fuel on the GME squeeze.”</p>\n<p>“There is no cop on the beat,” Einhorn writes. “Companies and managements that are emboldened enough to engage in malfeasance have little to fear.”</p>\n<p>With Greenlight returning just 5.2% in 2020—theS&amp;P 500returned 18%— Einhorn’s rant could seem like sour grapes if the issues he raises weren’t so serious.</p>\n<p>Einhorn calls on Congress to grill absentee regulators instead of interviewing Roaring Kitty.</p>\n<p>It would be a start.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hedge Fund Billionaire Who Shorted Lehman Brothers Says the Fed and SEC Aren’t Doing Their Jobs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHedge Fund Billionaire Who Shorted Lehman Brothers Says the Fed and SEC Aren’t Doing Their Jobs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 20:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/hedge-fund-billionaire-who-shorted-lehman-brothers-says-the-fed-and-sec-arent-doing-their-jobs-51618576593?mod=hp_LATEST><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks arehitting record highs, but not everyone is happy. Greenlight Capital’s David Einhorn is upset, particularly with regulators. He has a long list of gripes, ranging from the Federal Reserve’s ...</p>\n\n<a href=\"https://www.barrons.com/articles/hedge-fund-billionaire-who-shorted-lehman-brothers-says-the-fed-and-sec-arent-doing-their-jobs-51618576593?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.barrons.com/articles/hedge-fund-billionaire-who-shorted-lehman-brothers-says-the-fed-and-sec-arent-doing-their-jobs-51618576593?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131521200","content_text":"Stocks arehitting record highs, but not everyone is happy. Greenlight Capital’s David Einhorn is upset, particularly with regulators. He has a long list of gripes, ranging from the Federal Reserve’s handling of inflation to the U.S. Securities and Exchange Commission’s lack of action on everything from Robinhood toGameStop.\nEinhorn’s complaints regarding the Fed are boilerplate. The Fed has the job of keeping inflation in check, but is now willing to let inflation rise above its long-term target. He doesn’t like the new laissez-faire attitude about rising prices.\nBut Einhorn’s harshest words in a letter published Thursday were reserved for the SEC. Its job is to ensure fair trading, but Einhorn writes that it seems to have no interest in investigating spikes in the stock prices of tiny companies or statements from prominent figures such asTesla’sElon Musk and Chamath Palihapitiya that he likens to pouring “jet fuel on the GME squeeze.”\n“There is no cop on the beat,” Einhorn writes. “Companies and managements that are emboldened enough to engage in malfeasance have little to fear.”\nWith Greenlight returning just 5.2% in 2020—theS&P 500returned 18%— Einhorn’s rant could seem like sour grapes if the issues he raises weren’t so serious.\nEinhorn calls on Congress to grill absentee regulators instead of interviewing Roaring Kitty.\nIt would be a start.","news_type":1},"isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":370653608,"gmtCreate":1618582281204,"gmtModify":1704713082145,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"&nbsp;goooooo","listText":"&nbsp;goooooo","text":"goooooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/370653608","repostId":"1129784629","repostType":4,"repost":{"id":"1129784629","pubTimestamp":1618580943,"share":"https://ttm.financial/m/news/1129784629?lang=&edition=fundamental","pubTime":"2021-04-16 21:49","market":"us","language":"en","title":"DraftKings, Caesars and FanDuel ready for action after historic NFL sports betting deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1129784629","media":"seekingalpha","summary":"Oppenheimer weighs in on the big news from the sports world that the NFL will officially embrace onl","content":"<p>Oppenheimer weighs in on the big news from the sports world that the NFL will officially embrace online sports bettingby naming DraftKings&nbsp;(NASDAQ:DKNG), Caesars Entertainment(NASDAQ:CZR)and FanDuel as its first three official betting partners.</p><p>Analyst Jed Kelly and team see the development accelerating legalization and increasing consumer adoption. It is expected that the NFL will likely change its policy allow gambling commercials during its broadcasts.</p><p>\"Additionally, we believe this will benefit in-game wagering, where we now expect the league to work more closely with its media partners to reduce latency. Amazon, which will broadcast Thursday night games in either '22 or '23, is investing in technologies that reduce lag and improve streaming quality.\"</p><p>The NFL deals have a three-year initial term, with two one-year options for the NFL. All three will share the exclusive rights to use NFL intellectual property and expand the visibility of gambling in NFL owned-and-operated media. DraftKings can enhance its fan experience with game highlights, footage, and next-gen stats through its deal. Looking ahead, the NFL aims to add second tier sports book operators with less promotional activity. Fox Bet is expected to be one of the companies to get the authorization. Last month, Barclays haslifted its price targeton Fox(NASDAQ:FOXA), pointing to significant optionality in sports betting and iGaming through equity options linked to Flutter's (PDYPYD) Fanduel.</p><p>Shares of DraftKings are&nbsp;up 3.58% Penn National Gaming&nbsp;is&nbsp;up 0.91%. Caesars&nbsp;Entertainment is&nbsp;up 1.98%.</p><p><img src=\"https://static.tigerbbs.com/0f8a3a4b0a13098fd19d3783b62de84e\" tg-width=\"307\" tg-height=\"158\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DraftKings, Caesars and FanDuel ready for action after historic NFL sports betting deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDraftKings, Caesars and FanDuel ready for action after historic NFL sports betting deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 21:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3682598-draftkings-caesars-and-fanduel-ready-for-action-after-historic-nfl-sports-betting-deal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oppenheimer weighs in on the big news from the sports world that the NFL will officially embrace online sports bettingby naming DraftKings (NASDAQ:DKNG), Caesars Entertainment(NASDAQ:CZR)and FanDuel ...</p>\n\n<a href=\"https://seekingalpha.com/news/3682598-draftkings-caesars-and-fanduel-ready-for-action-after-historic-nfl-sports-betting-deal\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FOXA":"福克斯-A","DKNG":"DraftKings Inc.","PENN":"佩恩国民博彩","CZR":"凯撒娱乐"},"source_url":"https://seekingalpha.com/news/3682598-draftkings-caesars-and-fanduel-ready-for-action-after-historic-nfl-sports-betting-deal","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1129784629","content_text":"Oppenheimer weighs in on the big news from the sports world that the NFL will officially embrace online sports bettingby naming DraftKings (NASDAQ:DKNG), Caesars Entertainment(NASDAQ:CZR)and FanDuel as its first three official betting partners.Analyst Jed Kelly and team see the development accelerating legalization and increasing consumer adoption. It is expected that the NFL will likely change its policy allow gambling commercials during its broadcasts.\"Additionally, we believe this will benefit in-game wagering, where we now expect the league to work more closely with its media partners to reduce latency. Amazon, which will broadcast Thursday night games in either '22 or '23, is investing in technologies that reduce lag and improve streaming quality.\"The NFL deals have a three-year initial term, with two one-year options for the NFL. All three will share the exclusive rights to use NFL intellectual property and expand the visibility of gambling in NFL owned-and-operated media. DraftKings can enhance its fan experience with game highlights, footage, and next-gen stats through its deal. Looking ahead, the NFL aims to add second tier sports book operators with less promotional activity. Fox Bet is expected to be one of the companies to get the authorization. Last month, Barclays haslifted its price targeton Fox(NASDAQ:FOXA), pointing to significant optionality in sports betting and iGaming through equity options linked to Flutter's (PDYPYD) Fanduel.Shares of DraftKings are up 3.58% Penn National Gaming is up 0.91%. Caesars Entertainment is up 1.98%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344619783,"gmtCreate":1618405427142,"gmtModify":1704710281975,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Goooo","listText":"Goooo","text":"Goooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344619783","repostId":"1121209604","repostType":4,"repost":{"id":"1121209604","pubTimestamp":1618405158,"share":"https://ttm.financial/m/news/1121209604?lang=&edition=fundamental","pubTime":"2021-04-14 20:59","market":"us","language":"en","title":"Import/Export Prices Explode Higher In March, Hottest In A Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1121209604","media":"zerohedge","summary":"Amid global supply chain disruptions and trillions in liquidity to support consumption, it is perhap","content":"<p>Amid global supply chain disruptions and trillions in liquidity to support consumption, it is perhaps unsurprising that import and export price inflation is soaring.</p>\n<p>However, the scale of the moves is notable with import prices rising 1.2% MoM (+0.9% exp) and export prices rising 2.1% MoM (+1.0% exp).</p>\n<p>Sparking<b>the hottest inflationary prints in a decade (import prices +6.9% YoY, export prices +9.1% YoY)</b>...</p>\n<p><img src=\"https://static.tigerbbs.com/c82a044c05dcc4aa44e153ae1ac5f906\" tg-width=\"500\" tg-height=\"263\"><i>Source: Bloomberg</i></p>\n<p>China's decade-long export of deflation has abruptly stalled in recent months...</p>\n<p><img src=\"https://static.tigerbbs.com/85b8900b9545315587df1b394ea1dc05\" tg-width=\"500\" tg-height=\"270\"><i>Source: Bloomberg</i></p>\n<p>Perhaps more worrisome is that if historical relationships between China's Credit Impulse and trade inflation are anything to go by, import and export prices are set to soar even further</p>\n<p><img src=\"https://static.tigerbbs.com/95445840f5e05aa2052c34b914b7ad6f\" tg-width=\"500\" tg-height=\"267\"><i>Source: Bloomberg</i></p>\n<p>Still, nothing to worry about -<i><b>Mr.Powell has 'tools'.</b></i></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Import/Export Prices Explode Higher In March, Hottest In A Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImport/Export Prices Explode Higher In March, Hottest In A Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 20:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/economics/importexport-prices-explode-higher-march-hottest-decade?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amid global supply chain disruptions and trillions in liquidity to support consumption, it is perhaps unsurprising that import and export price inflation is soaring.\nHowever, the scale of the moves is...</p>\n\n<a href=\"https://www.zerohedge.com/economics/importexport-prices-explode-higher-march-hottest-decade?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.zerohedge.com/economics/importexport-prices-explode-higher-march-hottest-decade?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121209604","content_text":"Amid global supply chain disruptions and trillions in liquidity to support consumption, it is perhaps unsurprising that import and export price inflation is soaring.\nHowever, the scale of the moves is notable with import prices rising 1.2% MoM (+0.9% exp) and export prices rising 2.1% MoM (+1.0% exp).\nSparkingthe hottest inflationary prints in a decade (import prices +6.9% YoY, export prices +9.1% YoY)...\nSource: Bloomberg\nChina's decade-long export of deflation has abruptly stalled in recent months...\nSource: Bloomberg\nPerhaps more worrisome is that if historical relationships between China's Credit Impulse and trade inflation are anything to go by, import and export prices are set to soar even further\nSource: Bloomberg\nStill, nothing to worry about -Mr.Powell has 'tools'.","news_type":1},"isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":370653608,"gmtCreate":1618582281204,"gmtModify":1704713082145,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"&nbsp;goooooo","listText":"&nbsp;goooooo","text":"goooooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/370653608","repostId":"1129784629","repostType":4,"repost":{"id":"1129784629","pubTimestamp":1618580943,"share":"https://ttm.financial/m/news/1129784629?lang=&edition=fundamental","pubTime":"2021-04-16 21:49","market":"us","language":"en","title":"DraftKings, Caesars and FanDuel ready for action after historic NFL sports betting deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1129784629","media":"seekingalpha","summary":"Oppenheimer weighs in on the big news from the sports world that the NFL will officially embrace onl","content":"<p>Oppenheimer weighs in on the big news from the sports world that the NFL will officially embrace online sports bettingby naming DraftKings&nbsp;(NASDAQ:DKNG), Caesars Entertainment(NASDAQ:CZR)and FanDuel as its first three official betting partners.</p><p>Analyst Jed Kelly and team see the development accelerating legalization and increasing consumer adoption. It is expected that the NFL will likely change its policy allow gambling commercials during its broadcasts.</p><p>\"Additionally, we believe this will benefit in-game wagering, where we now expect the league to work more closely with its media partners to reduce latency. Amazon, which will broadcast Thursday night games in either '22 or '23, is investing in technologies that reduce lag and improve streaming quality.\"</p><p>The NFL deals have a three-year initial term, with two one-year options for the NFL. All three will share the exclusive rights to use NFL intellectual property and expand the visibility of gambling in NFL owned-and-operated media. DraftKings can enhance its fan experience with game highlights, footage, and next-gen stats through its deal. Looking ahead, the NFL aims to add second tier sports book operators with less promotional activity. Fox Bet is expected to be one of the companies to get the authorization. Last month, Barclays haslifted its price targeton Fox(NASDAQ:FOXA), pointing to significant optionality in sports betting and iGaming through equity options linked to Flutter's (PDYPYD) Fanduel.</p><p>Shares of DraftKings are&nbsp;up 3.58% Penn National Gaming&nbsp;is&nbsp;up 0.91%. Caesars&nbsp;Entertainment is&nbsp;up 1.98%.</p><p><img src=\"https://static.tigerbbs.com/0f8a3a4b0a13098fd19d3783b62de84e\" tg-width=\"307\" tg-height=\"158\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DraftKings, Caesars and FanDuel ready for action after historic NFL sports betting deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDraftKings, Caesars and FanDuel ready for action after historic NFL sports betting deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 21:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3682598-draftkings-caesars-and-fanduel-ready-for-action-after-historic-nfl-sports-betting-deal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oppenheimer weighs in on the big news from the sports world that the NFL will officially embrace online sports bettingby naming DraftKings (NASDAQ:DKNG), Caesars Entertainment(NASDAQ:CZR)and FanDuel ...</p>\n\n<a href=\"https://seekingalpha.com/news/3682598-draftkings-caesars-and-fanduel-ready-for-action-after-historic-nfl-sports-betting-deal\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FOXA":"福克斯-A","DKNG":"DraftKings Inc.","PENN":"佩恩国民博彩","CZR":"凯撒娱乐"},"source_url":"https://seekingalpha.com/news/3682598-draftkings-caesars-and-fanduel-ready-for-action-after-historic-nfl-sports-betting-deal","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1129784629","content_text":"Oppenheimer weighs in on the big news from the sports world that the NFL will officially embrace online sports bettingby naming DraftKings (NASDAQ:DKNG), Caesars Entertainment(NASDAQ:CZR)and FanDuel as its first three official betting partners.Analyst Jed Kelly and team see the development accelerating legalization and increasing consumer adoption. It is expected that the NFL will likely change its policy allow gambling commercials during its broadcasts.\"Additionally, we believe this will benefit in-game wagering, where we now expect the league to work more closely with its media partners to reduce latency. Amazon, which will broadcast Thursday night games in either '22 or '23, is investing in technologies that reduce lag and improve streaming quality.\"The NFL deals have a three-year initial term, with two one-year options for the NFL. All three will share the exclusive rights to use NFL intellectual property and expand the visibility of gambling in NFL owned-and-operated media. DraftKings can enhance its fan experience with game highlights, footage, and next-gen stats through its deal. Looking ahead, the NFL aims to add second tier sports book operators with less promotional activity. Fox Bet is expected to be one of the companies to get the authorization. Last month, Barclays haslifted its price targeton Fox(NASDAQ:FOXA), pointing to significant optionality in sports betting and iGaming through equity options linked to Flutter's (PDYPYD) Fanduel.Shares of DraftKings are up 3.58% Penn National Gaming is up 0.91%. Caesars Entertainment is up 1.98%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837054593,"gmtCreate":1629849811712,"gmtModify":1676530148776,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/837054593","repostId":"2162608721","repostType":4,"repost":{"id":"2162608721","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629847834,"share":"https://ttm.financial/m/news/2162608721?lang=&edition=fundamental","pubTime":"2021-08-25 07:30","market":"us","language":"en","title":"Eyewear maker Warby Parker to go public via direct listing on NYSE","url":"https://stock-news.laohu8.com/highlight/detail?id=2162608721","media":"Reuters","summary":"Aug 24 (Reuters) - Eyewear company Warby Parker on Tuesday filed paperwork with U.S. regulators for ","content":"<p>Aug 24 (Reuters) - Eyewear company Warby Parker on Tuesday filed paperwork with U.S. regulators for a direct listing on the New York Stock Exchange, revealing a 53% surge in revenue for the first half of 2021.</p>\n<p>The company, whose existing investors include Tiger Global Management and General Catalyst, did not disclose the number of Class A common shares its stockholders were looking to sell. It will not receive any proceeds from the sale of such shares.</p>\n<p>The New York-based firm, known for its fashionable eyewear starting at $95, was valued at $3 billion after a $245 million funding round in 2020, the Wall Street Journal had reported</p>\n<p>The co-founders of Warby, who were classmates at the Wharton School of the University of Pennsylvania, got the idea for the company in 2008 after co-Chief Executive Officer Dave Gilboa found the cost of replacing eyeglasses lost on a Southeast Asia backpacking trip to be too high.</p>\n<p>Founded later in 2010, the company now has an active consumer base that exceeds two million as rising usage of smartphones, tablets and other devices increases the need for vision correction.</p>\n<p>A direct listing like Warby's allows companies to list their stock on public exchanges by sidestepping a costly and time-consuming initial public offering.</p>\n<p>The U.S. Securities and Exchange Commission approved a Nasdaq Inc&nbsp;proposal to allow companies to raise capital through direct listings in May. Companies have not raised any capital through such listing procedures so far.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eyewear maker Warby Parker to go public via direct listing on NYSE</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyewear maker Warby Parker to go public via direct listing on NYSE\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-25 07:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 24 (Reuters) - Eyewear company Warby Parker on Tuesday filed paperwork with U.S. regulators for a direct listing on the New York Stock Exchange, revealing a 53% surge in revenue for the first half of 2021.</p>\n<p>The company, whose existing investors include Tiger Global Management and General Catalyst, did not disclose the number of Class A common shares its stockholders were looking to sell. It will not receive any proceeds from the sale of such shares.</p>\n<p>The New York-based firm, known for its fashionable eyewear starting at $95, was valued at $3 billion after a $245 million funding round in 2020, the Wall Street Journal had reported</p>\n<p>The co-founders of Warby, who were classmates at the Wharton School of the University of Pennsylvania, got the idea for the company in 2008 after co-Chief Executive Officer Dave Gilboa found the cost of replacing eyeglasses lost on a Southeast Asia backpacking trip to be too high.</p>\n<p>Founded later in 2010, the company now has an active consumer base that exceeds two million as rising usage of smartphones, tablets and other devices increases the need for vision correction.</p>\n<p>A direct listing like Warby's allows companies to list their stock on public exchanges by sidestepping a costly and time-consuming initial public offering.</p>\n<p>The U.S. Securities and Exchange Commission approved a Nasdaq Inc&nbsp;proposal to allow companies to raise capital through direct listings in May. Companies have not raised any capital through such listing procedures so far.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162608721","content_text":"Aug 24 (Reuters) - Eyewear company Warby Parker on Tuesday filed paperwork with U.S. regulators for a direct listing on the New York Stock Exchange, revealing a 53% surge in revenue for the first half of 2021.\nThe company, whose existing investors include Tiger Global Management and General Catalyst, did not disclose the number of Class A common shares its stockholders were looking to sell. It will not receive any proceeds from the sale of such shares.\nThe New York-based firm, known for its fashionable eyewear starting at $95, was valued at $3 billion after a $245 million funding round in 2020, the Wall Street Journal had reported\nThe co-founders of Warby, who were classmates at the Wharton School of the University of Pennsylvania, got the idea for the company in 2008 after co-Chief Executive Officer Dave Gilboa found the cost of replacing eyeglasses lost on a Southeast Asia backpacking trip to be too high.\nFounded later in 2010, the company now has an active consumer base that exceeds two million as rising usage of smartphones, tablets and other devices increases the need for vision correction.\nA direct listing like Warby's allows companies to list their stock on public exchanges by sidestepping a costly and time-consuming initial public offering.\nThe U.S. Securities and Exchange Commission approved a Nasdaq Inc proposal to allow companies to raise capital through direct listings in May. Companies have not raised any capital through such listing procedures so far.","news_type":1},"isVote":1,"tweetType":1,"viewCount":446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377216529,"gmtCreate":1619530397761,"gmtModify":1704725481664,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/377216529","repostId":"1155157199","repostType":4,"repost":{"id":"1155157199","pubTimestamp":1619494851,"share":"https://ttm.financial/m/news/1155157199?lang=&edition=fundamental","pubTime":"2021-04-27 11:40","market":"us","language":"en","title":"Microsoft Nears $2 Trillion Market Cap. Earnings Are Tuesday.","url":"https://stock-news.laohu8.com/highlight/detail?id=1155157199","media":"Barrons","summary":"Wall Street is expecting Microsoft to report strong financial results when the company posts its March quarter numbers after the close of trading on Tuesday.The consensus forecast among analysts is for revenue of $41 billion, up 17% from a year ago, with profits of $1.78 a share.  On Monday, Microsoft stock set an intraday record of $262.44, leaving the stock just a modest rally away from hitting a $2 trillion valuation for the first time. To get there, the stock needs to rise to $264.55.J.P. Mo","content":"<p>Wall Street is expecting Microsoft to report strong financial results when the company posts its March quarter numbers after the close of trading on Tuesday.</p><p>The consensus forecast among analysts is for revenue of $41 billion, up 17% from a year ago, with profits of $1.78 a share.&nbsp; On Monday, Microsoft stock set an intraday record of $262.44, leaving the stock just a modest rally away from hitting a $2 trillion valuation for the first time. To get there, the stock needs to rise to $264.55.</p><p>The shares have gained 18% year to date.</p><p>Analysts expect another strong quarter from the company’s Azure and Office 365 cloud businesses, and will be looking for signs of accelerating growth in its enterprise operation. Sales of Surface hardware—laptops and whiteboards—were likely strong in the quarter, given the huge recent growth in PC purchases, although there is some potential that shortages of components resulted in unfilled demand. Strength in the PC market also bodes well for sales of the Windows operating system.&nbsp;</p><p>Microsoft breaks down its results into&nbsp;three segments: Productivity and Business Processes, which includes Office 365, Dynamics, and LinkedIn; Intelligence Cloud, which includes Azure and enterprise server software; and More Personal Computing, which includes Windows, Xbox, Surface hardware, and Bing.</p><p>When Microsoft reported its results for its fiscal second quarter in late January,CFO Amy Hood provided revenue guidance for each segment. For Productivity and Business Processes, she projected revenue of $13.35 billion to $13.6 billion. The call for Intelligent Cloud was for revenue of $14.7 billion to $14.95 billion, while she predicted $12.3 billion to $12.7 billion for More Personal Computing. If revenue for each segment came in at the top of its forecast range, the total would be $41.25 billion.</p><p>In research notes, several analysts cited positive comments from customers and resellers in projecting strong results.</p><p>Last week, KeyBanc Capital’s Michael Turits repeated his Overweight rating on the stock while lifting his target for the price to $295, from $280. He says the company is likely benefiting from a combination of strong IT demand and continuing strength in PC shipments.</p><p>“We continue to see Microsoft’s combination of expanding Azure scope, broad enterprise application innovation, and aggressive bundling seeing success in the market,” he wrote. “Nearly all North American Microsoft distributors/resellers we spoke with reported Microsoft channel revenue on or above plan.”</p><p>J.P. Morgan analyst Mark Murphy came away from his own new survey of resellers of Microsoft products encouraged about the outlook. He says those companies’ quarterly sales of Microsoft goods came in an average of 3.3% above their expectations, driven by improving enterprise demand. He reported strength across the company’s enterprise product lines, with growth in Azure, Teams, Office 365, and security products, among other places. Murphy rates Microsoft at Overweight and has a target of $245 for the stock price.</p><p>Wedbush analyst Dan Ives&nbsp;forecast “another masterpiece quarter,” driven by growth of at least 45% from Azure, which he thinks is taking market share from Amazon Web Services. He said the current work-from-home environment is encouraging more businesses to make strategic moves toward cloud-based operations “with Microsoft across the board with Azure growth remaining brisk.” He maintained an Outperform rating, with a target of $300 for the share price.</p><p>Citi analyst Tyler Radke&nbsp;last week reiterated a Buy rating on Microsoft shares, lifting his price target to $302, from $292, and setting a “positive catalyst watch” on the stock ahead of the results. He wrote that a combination of a survey of resellers and channel checks made him more confident that Microsoft can propel revenue across all three primary business segments, with strength in personal computer demand from both consumers and businesses, robust upgrade activity on server software, and continued strength in Azure as a result of “continued strong enterprise consumption growth.”&nbsp;</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft Nears $2 Trillion Market Cap. Earnings Are Tuesday.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft Nears $2 Trillion Market Cap. Earnings Are Tuesday.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/microsoft-nears-2-trillion-market-cap-earnings-are-tuesday-51619457928?mod=hp_DAY_Theme_2_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street is expecting Microsoft to report strong financial results when the company posts its March quarter numbers after the close of trading on Tuesday.The consensus forecast among analysts is ...</p>\n\n<a href=\"https://www.barrons.com/articles/microsoft-nears-2-trillion-market-cap-earnings-are-tuesday-51619457928?mod=hp_DAY_Theme_2_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://www.barrons.com/articles/microsoft-nears-2-trillion-market-cap-earnings-are-tuesday-51619457928?mod=hp_DAY_Theme_2_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155157199","content_text":"Wall Street is expecting Microsoft to report strong financial results when the company posts its March quarter numbers after the close of trading on Tuesday.The consensus forecast among analysts is for revenue of $41 billion, up 17% from a year ago, with profits of $1.78 a share.  On Monday, Microsoft stock set an intraday record of $262.44, leaving the stock just a modest rally away from hitting a $2 trillion valuation for the first time. To get there, the stock needs to rise to $264.55.The shares have gained 18% year to date.Analysts expect another strong quarter from the company’s Azure and Office 365 cloud businesses, and will be looking for signs of accelerating growth in its enterprise operation. Sales of Surface hardware—laptops and whiteboards—were likely strong in the quarter, given the huge recent growth in PC purchases, although there is some potential that shortages of components resulted in unfilled demand. Strength in the PC market also bodes well for sales of the Windows operating system. Microsoft breaks down its results into three segments: Productivity and Business Processes, which includes Office 365, Dynamics, and LinkedIn; Intelligence Cloud, which includes Azure and enterprise server software; and More Personal Computing, which includes Windows, Xbox, Surface hardware, and Bing.When Microsoft reported its results for its fiscal second quarter in late January,CFO Amy Hood provided revenue guidance for each segment. For Productivity and Business Processes, she projected revenue of $13.35 billion to $13.6 billion. The call for Intelligent Cloud was for revenue of $14.7 billion to $14.95 billion, while she predicted $12.3 billion to $12.7 billion for More Personal Computing. If revenue for each segment came in at the top of its forecast range, the total would be $41.25 billion.In research notes, several analysts cited positive comments from customers and resellers in projecting strong results.Last week, KeyBanc Capital’s Michael Turits repeated his Overweight rating on the stock while lifting his target for the price to $295, from $280. He says the company is likely benefiting from a combination of strong IT demand and continuing strength in PC shipments.“We continue to see Microsoft’s combination of expanding Azure scope, broad enterprise application innovation, and aggressive bundling seeing success in the market,” he wrote. “Nearly all North American Microsoft distributors/resellers we spoke with reported Microsoft channel revenue on or above plan.”J.P. Morgan analyst Mark Murphy came away from his own new survey of resellers of Microsoft products encouraged about the outlook. He says those companies’ quarterly sales of Microsoft goods came in an average of 3.3% above their expectations, driven by improving enterprise demand. He reported strength across the company’s enterprise product lines, with growth in Azure, Teams, Office 365, and security products, among other places. Murphy rates Microsoft at Overweight and has a target of $245 for the stock price.Wedbush analyst Dan Ives forecast “another masterpiece quarter,” driven by growth of at least 45% from Azure, which he thinks is taking market share from Amazon Web Services. He said the current work-from-home environment is encouraging more businesses to make strategic moves toward cloud-based operations “with Microsoft across the board with Azure growth remaining brisk.” He maintained an Outperform rating, with a target of $300 for the share price.Citi analyst Tyler Radke last week reiterated a Buy rating on Microsoft shares, lifting his price target to $302, from $292, and setting a “positive catalyst watch” on the stock ahead of the results. He wrote that a combination of a survey of resellers and channel checks made him more confident that Microsoft can propel revenue across all three primary business segments, with strength in personal computer demand from both consumers and businesses, robust upgrade activity on server software, and continued strength in Azure as a result of “continued strong enterprise consumption growth.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344619783,"gmtCreate":1618405427142,"gmtModify":1704710281975,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Goooo","listText":"Goooo","text":"Goooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344619783","repostId":"1121209604","repostType":4,"repost":{"id":"1121209604","pubTimestamp":1618405158,"share":"https://ttm.financial/m/news/1121209604?lang=&edition=fundamental","pubTime":"2021-04-14 20:59","market":"us","language":"en","title":"Import/Export Prices Explode Higher In March, Hottest In A Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1121209604","media":"zerohedge","summary":"Amid global supply chain disruptions and trillions in liquidity to support consumption, it is perhap","content":"<p>Amid global supply chain disruptions and trillions in liquidity to support consumption, it is perhaps unsurprising that import and export price inflation is soaring.</p>\n<p>However, the scale of the moves is notable with import prices rising 1.2% MoM (+0.9% exp) and export prices rising 2.1% MoM (+1.0% exp).</p>\n<p>Sparking<b>the hottest inflationary prints in a decade (import prices +6.9% YoY, export prices +9.1% YoY)</b>...</p>\n<p><img src=\"https://static.tigerbbs.com/c82a044c05dcc4aa44e153ae1ac5f906\" tg-width=\"500\" tg-height=\"263\"><i>Source: Bloomberg</i></p>\n<p>China's decade-long export of deflation has abruptly stalled in recent months...</p>\n<p><img src=\"https://static.tigerbbs.com/85b8900b9545315587df1b394ea1dc05\" tg-width=\"500\" tg-height=\"270\"><i>Source: Bloomberg</i></p>\n<p>Perhaps more worrisome is that if historical relationships between China's Credit Impulse and trade inflation are anything to go by, import and export prices are set to soar even further</p>\n<p><img src=\"https://static.tigerbbs.com/95445840f5e05aa2052c34b914b7ad6f\" tg-width=\"500\" tg-height=\"267\"><i>Source: Bloomberg</i></p>\n<p>Still, nothing to worry about -<i><b>Mr.Powell has 'tools'.</b></i></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Import/Export Prices Explode Higher In March, Hottest In A Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImport/Export Prices Explode Higher In March, Hottest In A Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 20:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/economics/importexport-prices-explode-higher-march-hottest-decade?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amid global supply chain disruptions and trillions in liquidity to support consumption, it is perhaps unsurprising that import and export price inflation is soaring.\nHowever, the scale of the moves is...</p>\n\n<a href=\"https://www.zerohedge.com/economics/importexport-prices-explode-higher-march-hottest-decade?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.zerohedge.com/economics/importexport-prices-explode-higher-march-hottest-decade?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121209604","content_text":"Amid global supply chain disruptions and trillions in liquidity to support consumption, it is perhaps unsurprising that import and export price inflation is soaring.\nHowever, the scale of the moves is notable with import prices rising 1.2% MoM (+0.9% exp) and export prices rising 2.1% MoM (+1.0% exp).\nSparkingthe hottest inflationary prints in a decade (import prices +6.9% YoY, export prices +9.1% YoY)...\nSource: Bloomberg\nChina's decade-long export of deflation has abruptly stalled in recent months...\nSource: Bloomberg\nPerhaps more worrisome is that if historical relationships between China's Credit Impulse and trade inflation are anything to go by, import and export prices are set to soar even further\nSource: Bloomberg\nStill, nothing to worry about -Mr.Powell has 'tools'.","news_type":1},"isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161774535,"gmtCreate":1623942304627,"gmtModify":1703824222248,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Go","listText":"Go","text":"Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161774535","repostId":"1175322624","repostType":4,"repost":{"id":"1175322624","pubTimestamp":1623940991,"share":"https://ttm.financial/m/news/1175322624?lang=&edition=fundamental","pubTime":"2021-06-17 22:43","market":"us","language":"en","title":"Fisker Jumps on EV-Production Pact With Magna International","url":"https://stock-news.laohu8.com/highlight/detail?id=1175322624","media":".thestreet","summary":"Fisker   was higher after it said it signed an agreement under which Magna International,  the mobility technology company, would produce its electric vehicles.As part of the partnership, Fisker's all-electric Ocean SUV is expected to start production at the Aurora, Ontario, company's facility in Graz, Austria, starting Nov. 17, 2022.\"From the start of this partnership, Fisker and Magna aligned very quickly on the importance of delivering a high-quality vehicle on time,\" Chief Executive Henrik F","content":"<p>Fisker&nbsp;(<b>FSR</b>) &nbsp;was higher after it&nbsp;said&nbsp;it signed an agreement under which Magna International,&nbsp;(<b>MGA</b>)&nbsp;the mobility technology company, would produce its electric vehicles.</p>\n<p>As part of the partnership, Fisker's all-electric Ocean SUV is expected to start production at the Aurora, Ontario, company's facility in Graz, Austria, starting Nov. 17, 2022.</p>\n<p>\"From the start of this partnership, Fisker and Magna aligned very quickly on the importance of delivering a high-quality vehicle on time,\" Chief Executive Henrik Fisker said in a statement.</p>\n<p>The Graz manufacturing facility has produced more than 3.7 million vehicles for several global automakers.</p>\n<p>The agreement is \"broad-based\" covering planned volumes, manufacturing costs and quality metrics over the program's lifecycle which runs through 2029.</p>\n<p>The Ocean SUV from the Los Angeles company will use a version of a Magna-developed electric-vehicle architecture. Fisker will modify that architecture to create new intellectual property that it expects to deliver \"class-leading range\" while also lowering manufacturing costs.</p>\n<p>Fisker now expects Ocean to enter the market with a starting list price of $37,499 in the U.S., excluding electric vehicle-related subsidies, and below&nbsp;€32,000 ($38,200) in Germany (including taxes and EV-related subsidies).</p>\n<p>\"Our asset-lite model, reinforced by partners like Magna, is powering Fisker towards its planned delivery of the Ocean with features and functions exceeding our original aspirations,\" said Fisker. He added that the company is scaling rapidly.</p>\n<p>Fisker shares at last check were 3.1% higher at $18.29. Magna's shares traded on the New York Stock Exchange were off 0.5% at $92.74.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fisker Jumps on EV-Production Pact With Magna International</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFisker Jumps on EV-Production Pact With Magna International\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/fisker-higher-after-finalizing-magna-intl-production-agreement><strong>.thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fisker (FSR)  was higher after it said it signed an agreement under which Magna International, (MGA) the mobility technology company, would produce its electric vehicles.\nAs part of the partnership, ...</p>\n\n<a href=\"https://www.thestreet.com/investing/fisker-higher-after-finalizing-magna-intl-production-agreement\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSR":"菲斯克"},"source_url":"https://www.thestreet.com/investing/fisker-higher-after-finalizing-magna-intl-production-agreement","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175322624","content_text":"Fisker (FSR)  was higher after it said it signed an agreement under which Magna International, (MGA) the mobility technology company, would produce its electric vehicles.\nAs part of the partnership, Fisker's all-electric Ocean SUV is expected to start production at the Aurora, Ontario, company's facility in Graz, Austria, starting Nov. 17, 2022.\n\"From the start of this partnership, Fisker and Magna aligned very quickly on the importance of delivering a high-quality vehicle on time,\" Chief Executive Henrik Fisker said in a statement.\nThe Graz manufacturing facility has produced more than 3.7 million vehicles for several global automakers.\nThe agreement is \"broad-based\" covering planned volumes, manufacturing costs and quality metrics over the program's lifecycle which runs through 2029.\nThe Ocean SUV from the Los Angeles company will use a version of a Magna-developed electric-vehicle architecture. Fisker will modify that architecture to create new intellectual property that it expects to deliver \"class-leading range\" while also lowering manufacturing costs.\nFisker now expects Ocean to enter the market with a starting list price of $37,499 in the U.S., excluding electric vehicle-related subsidies, and below €32,000 ($38,200) in Germany (including taxes and EV-related subsidies).\n\"Our asset-lite model, reinforced by partners like Magna, is powering Fisker towards its planned delivery of the Ocean with features and functions exceeding our original aspirations,\" said Fisker. He added that the company is scaling rapidly.\nFisker shares at last check were 3.1% higher at $18.29. Magna's shares traded on the New York Stock Exchange were off 0.5% at $92.74.","news_type":1},"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375916271,"gmtCreate":1619275670193,"gmtModify":1704722042733,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375916271","repostId":"1179843002","repostType":4,"repost":{"id":"1179843002","pubTimestamp":1619190162,"share":"https://ttm.financial/m/news/1179843002?lang=&edition=fundamental","pubTime":"2021-04-23 23:02","market":"fut","language":"en","title":"‘Black Swan’ author calls bitcoin a ‘gimmick’ and a ‘game,’ says it resembles a Ponzi scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1179843002","media":"CNBC","summary":"KEY POINTS\n\n“Black Swan” author Nassim Taleb ripped bitcoin as a “gimmick” that’s too volatile to be","content":"<div>\n<p>KEY POINTS\n\n“Black Swan” author Nassim Taleb ripped bitcoin as a “gimmick” that’s too volatile to be a currency and an unsafe hedge against inflation.\n“Basically, there’s no connection between ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/23/bitcoin-a-gimmick-and-resembles-a-ponzi-scheme-black-swan-author-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>‘Black Swan’ author calls bitcoin a ‘gimmick’ and a ‘game,’ says it resembles a Ponzi scheme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n‘Black Swan’ author calls bitcoin a ‘gimmick’ and a ‘game,’ says it resembles a Ponzi scheme\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/23/bitcoin-a-gimmick-and-resembles-a-ponzi-scheme-black-swan-author-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\n“Black Swan” author Nassim Taleb ripped bitcoin as a “gimmick” that’s too volatile to be a currency and an unsafe hedge against inflation.\n“Basically, there’s no connection between ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/23/bitcoin-a-gimmick-and-resembles-a-ponzi-scheme-black-swan-author-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust","SQ":"Block","PYPL":"PayPal","TSLA":"特斯拉"},"source_url":"https://www.cnbc.com/2021/04/23/bitcoin-a-gimmick-and-resembles-a-ponzi-scheme-black-swan-author-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1179843002","content_text":"KEY POINTS\n\n“Black Swan” author Nassim Taleb ripped bitcoin as a “gimmick” that’s too volatile to be a currency and an unsafe hedge against inflation.\n“Basically, there’s no connection between inflation and bitcoin,” the former derivatives trader and current hedge fund advisor told CNBC on Friday.\nTaleb had once believed bitcoin was a promising new currency, because it was not controlled by a government. But he has since changed his mind.\n\n“Black Swan” author Nassim Taleb on Friday criticized bitcoin as a “gimmick,” telling CNBC he believes it’s too volatile to be an effective currency and it’s not a safe hedge against inflation.\n“Basically, there’s no connection between inflation and bitcoin. None. I mean, you can have hyperinflation and bitcoin going to zero. There’s no link between them,” Taleb said in a “Squawk Box” interview.\n“It’s a beautifully set up cryptographic system. It’s well made but there’s absolutely no reason it should be linked to anything economic,” added Taleb, whose bestselling 2007 book examined highly improbable events and their potential to cause severe consequences. He said bitcoin has characteristics of what he calls a Ponzi scheme that’s right out in the open.\nA Ponzi scheme is a type of fraud whereby crooks steal money from investors and mask the theft by funneling returns to clients from funds contributed by newer investors.\nTaleb had once held favorable views toward bitcoin, which was created in 2009 and is the world’s largest cryptocurrency by market value. However, he told CNBC he was “fooled by it initially” because he thought it could develop into a currency used in transactions.\n“Something that moves 5% a day, 20% in a month — up or down — cannot be a currency. It’s something else,” said Taleb, a former derivatives trader who serves as scientific advisor to hedge fund Universa Investments.\n“I bought into it ... not willing to have capital appreciation, so much as wanting to have an alternative to the fiat currency issued by central banks: A currency without a government,” Taleb said. “I realized it was not a currency without a government. It was just pure speculation. It’s just like a game ... I mean, you can create another game and call it a currency.”\nWhile some businesses do accept bitcoin as payment for goods and services, including electric vehicle maker Tesla, there are those in the crypto community who think it’s actually an asset and store of value. Bitcoin, which has its supply capped at 21 million tokens, has been described as “digital gold.”\n“It’s easily transportable and can be sent anywhere in the world if you have a smartphone so it’s a much better version, as a store of value, than gold,” famed value investor Bill Miller told CNBC earlier this week.\n“With bitcoin, volatility is the price you pay for performance,” added Miller, who has also previously contended bitcoin grows less risky as adoption and its price increases.\nIndeed, the price of bitcoin has soared higher in recent months — rising from under $11,000 per unit as recently as October to an all-time high of nearly $65,000 last week. Increased institutional adoption has been cited as one factor in its climb.\nIn keeping with its propensity for wild price swings, bitcoin has tumbled in the days since, ultimately breaking below $50,000 per token earlier Friday, a 23% drop in a little more than a week. However, the price has still risen more than 70% year to date,according to Coindesk.\nBitcoin has received long-term price targets between $400,000 and $600,000 per token from some people in the investment community, including Guggenheim Partners’Scott Minerd; others have projected even higher than that.\nTaleb suggested bitcoin’s price is not what informs his now-critical view, saying “bitcoin could go to $1 million” and it wouldn’t change his argument. “These gimmicks, you have bitcoin today. You may have another one tomorrow. They come and go, and there’s no systematic link between them and the claims they make,” he added.\nInvestors who are worried about inflation would be better off purchasing property than investing in bitcoin, Taleb said. “If you want to hedge against inflation, buy a piece of land. Grow, I don’t know, olives on it. You’ll have olive oil. If the price collapses, you’ll have something.”\n“But bitcoin, there’s no connection and, of course, the best strategy for investors is to own things that produce yields in the future. In other words, you can fall back on real dollars coming out of the company,” he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379508528,"gmtCreate":1618755946064,"gmtModify":1704714617173,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Zzzz","listText":"Zzzz","text":"Zzzz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379508528","repostId":"1131521200","repostType":4,"repost":{"id":"1131521200","pubTimestamp":1618577973,"share":"https://ttm.financial/m/news/1131521200?lang=&edition=fundamental","pubTime":"2021-04-16 20:59","market":"us","language":"en","title":"Hedge Fund Billionaire Who Shorted Lehman Brothers Says the Fed and SEC Aren’t Doing Their Jobs","url":"https://stock-news.laohu8.com/highlight/detail?id=1131521200","media":"Barron's","summary":"Stocks arehitting record highs, but not everyone is happy. Greenlight Capital’s David Einhorn is ups","content":"<p>Stocks arehitting record highs, but not everyone is happy. Greenlight Capital’s David Einhorn is upset, particularly with regulators. He has a long list of gripes, ranging from the Federal Reserve’s handling of inflation to the U.S. Securities and Exchange Commission’s lack of action on everything from Robinhood toGameStop.</p>\n<p>Einhorn’s complaints regarding the Fed are boilerplate. The Fed has the job of keeping inflation in check, but is now willing to let inflation rise above its long-term target. He doesn’t like the new laissez-faire attitude about rising prices.</p>\n<p>But Einhorn’s harshest words in a letter published Thursday were reserved for the SEC. Its job is to ensure fair trading, but Einhorn writes that it seems to have no interest in investigating spikes in the stock prices of tiny companies or statements from prominent figures such asTesla’sElon Musk and Chamath Palihapitiya that he likens to pouring “jet fuel on the GME squeeze.”</p>\n<p>“There is no cop on the beat,” Einhorn writes. “Companies and managements that are emboldened enough to engage in malfeasance have little to fear.”</p>\n<p>With Greenlight returning just 5.2% in 2020—theS&amp;P 500returned 18%— Einhorn’s rant could seem like sour grapes if the issues he raises weren’t so serious.</p>\n<p>Einhorn calls on Congress to grill absentee regulators instead of interviewing Roaring Kitty.</p>\n<p>It would be a start.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hedge Fund Billionaire Who Shorted Lehman Brothers Says the Fed and SEC Aren’t Doing Their Jobs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHedge Fund Billionaire Who Shorted Lehman Brothers Says the Fed and SEC Aren’t Doing Their Jobs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 20:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/hedge-fund-billionaire-who-shorted-lehman-brothers-says-the-fed-and-sec-arent-doing-their-jobs-51618576593?mod=hp_LATEST><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks arehitting record highs, but not everyone is happy. Greenlight Capital’s David Einhorn is upset, particularly with regulators. He has a long list of gripes, ranging from the Federal Reserve’s ...</p>\n\n<a href=\"https://www.barrons.com/articles/hedge-fund-billionaire-who-shorted-lehman-brothers-says-the-fed-and-sec-arent-doing-their-jobs-51618576593?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.barrons.com/articles/hedge-fund-billionaire-who-shorted-lehman-brothers-says-the-fed-and-sec-arent-doing-their-jobs-51618576593?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131521200","content_text":"Stocks arehitting record highs, but not everyone is happy. Greenlight Capital’s David Einhorn is upset, particularly with regulators. He has a long list of gripes, ranging from the Federal Reserve’s handling of inflation to the U.S. Securities and Exchange Commission’s lack of action on everything from Robinhood toGameStop.\nEinhorn’s complaints regarding the Fed are boilerplate. The Fed has the job of keeping inflation in check, but is now willing to let inflation rise above its long-term target. He doesn’t like the new laissez-faire attitude about rising prices.\nBut Einhorn’s harshest words in a letter published Thursday were reserved for the SEC. Its job is to ensure fair trading, but Einhorn writes that it seems to have no interest in investigating spikes in the stock prices of tiny companies or statements from prominent figures such asTesla’sElon Musk and Chamath Palihapitiya that he likens to pouring “jet fuel on the GME squeeze.”\n“There is no cop on the beat,” Einhorn writes. “Companies and managements that are emboldened enough to engage in malfeasance have little to fear.”\nWith Greenlight returning just 5.2% in 2020—theS&P 500returned 18%— Einhorn’s rant could seem like sour grapes if the issues he raises weren’t so serious.\nEinhorn calls on Congress to grill absentee regulators instead of interviewing Roaring Kitty.\nIt would be a start.","news_type":1},"isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":254449493717208,"gmtCreate":1703158233468,"gmtModify":1703158236547,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/254449493717208","repostId":"248312805347464","repostType":1,"repost":{"id":248312805347464,"gmtCreate":1701660745864,"gmtModify":1703059991513,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"🐅🌟 TIGER TYCOON CHALLENGE IS ON! 🌟🐅","htmlText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","listText":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct &amp; Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","text":"Hey Tycoons! 🎩💼 Ready to embark on the adventure of a lifetime? Introducing the Tiger Tycoon Challenge – where fortunes are made, and USD 888 worth of prizes await the boldest players! 🏰🌈🎯 Objective: Build your empire, score big points, and unlock fabulous rewards!💰 Gold Rush: Grab those shiny gold coins every time you pass by it! Cha-ching! 💰💵🏠 Construct & Conquer: Step on an empty tile to construct a building to gain points! 🏰🏆 Prizes Galore: Hit the prize tile to claim your treasure – it could be anything! 🎁✨🔄 Lucky Draw: Land on the draw tile and brace yourself! You might move forward, backward, or even unlock a secret power! 🔄🔮🚀 Airdrop Alert: Keep your eyes on the sky! Periodically, the Tiger Tycoon map will rain down special rewards like stocks, vouchers, and more. Fastest finge","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/248312805347464","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009143889,"gmtCreate":1640579576165,"gmtModify":1676533527250,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"go","listText":"go","text":"go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009143889","repostId":"2194177136","repostType":4,"repost":{"id":"2194177136","pubTimestamp":1640572338,"share":"https://ttm.financial/m/news/2194177136?lang=&edition=fundamental","pubTime":"2021-12-27 10:32","market":"us","language":"en","title":"3 Biotech Stocks That Sank in 2021 but Could Soar in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2194177136","media":"Motley Fool","summary":"These stocks could rebound nicely in the new year.","content":"<p>There's no denying that 2021 has been a rough year for many biotech stocks. The shares of quite a few big and small biotech companies alike are set to finish the year in negative territory. But those disappointing performances won't necessarily extend into the future.</p>\n<p>We asked three Motley Fool contributors to pick biotech stocks that sank in 2021 but could soar in 2022. Here's why they chose <a href=\"https://laohu8.com/S/AXSM\"><b>Axsome Therapeutics</b> </a>, <a href=\"https://laohu8.com/S/NVS\"><b>Novartis</b> </a>, and <a href=\"https://laohu8.com/S/VRTX\"><b>Vertex Pharmaceuticals</b> </a>.</p>\n<h2>Long-term catalysts abound for this biotech</h2>\n<p><b>Prosper Junior Bakiny (Axsome Therapeutics):</b> Shares of Axsome Therapeutics have dropped by more than 50% this year. The company has had to deal with various setbacks. Most notably, the regulatory review of Axsome Therapeutics' lead pipeline candidate, AXS-05, was delayed. The Food and Drug Administration (FDA) was supposed to complete its review of the potential therapy for major depressive disorder in late August.</p>\n<p>But the agency found deficiencies in Axsome Therapeutics' application. As a result, the FDA has yet to approve the drug. While this issue hurt Axsome Therapeutics' stock performance, the future looks bright for the company. AXS-05 proved effective at reducing the symptoms of depression in a late-stage study.</p>\n<p>The need for a medicine like AXS-05 has only increased as a result of the pandemic, with the number of people suffering from symptoms of depression nearly quadrupling to 80 million since the outbreak started. AXS-05's delayed review isn't ideal, to say the least. But given the solid results it delivered in clinical trials and the dire need for depression therapies, it looks likely to hit the market eventually.</p>\n<p>But Axsome Therapeutics is also developing several other medicines. These include AXS-07, a potential treatment for migraines, and AXS-12 and AXS-14, aimed at treating narcolepsy and fibromyalgia, respectively. The company estimates the potential annual sales of these medicines to be between $4 billion and $9 billion.</p>\n<p>Meanwhile, Axsome Therapeutics' market cap of $1.4 billion is currently less than half of the low end of these projections. That gives Axsome Therapeutics a tremendous upside potential. Naturally, risks are involved; the company could run into more regulatory roadblocks for AXS-05 or some other pipeline candidate.</p>\n<p>But on the flip side, if Axsome Therapeutics starts racking up regulatory approvals for its therapies, its shares will soar next year and beyond. While I wouldn't recommend going all-in on this company -- it'd be best to initiate a small position, for now -- 2022 could prove to be a much better year for the biotech.</p>\n<h2>Ready to take off</h2>\n<p><b>David Jagielski</b>&nbsp;<b>(Novartis):&nbsp;</b>Investors have been moving away from high-priced growth stocks and into more value-oriented investments in recent weeks. One stock that has benefited from that is healthcare company Novartis, which is up over 5% in the past month while the <b>S&amp;P 500</b> has fallen 2%. The drugmaker's shares are still down 9% year to date. But if the shift to value stocks continues, Novartis may continue climbing into next year.</p>\n<p>The business itself is in solid shape. Novartis posted a profit of $9.8 billion on sales of $52.4 billion over the trailing 12 months, good for a profit margin of just under 19%. It has also generated a boatload of money, with free cash flow during that time coming in at $12.2 billion. And the company is getting even more cash into its financials after selling its stake in drugmaker <b>Roche</b>&nbsp;for $20.7 billion. As a result of this windfall of cash, the company is planning to buy back up to $15 billion worth of its shares by the end of 2023.</p>\n<p>Cash is king, and Novartis is generating plenty of it these days. That will give the company lots of flexibility moving forward should it want to pursue an acquisition or invest in expanding its business in other ways. Novartis projects that through new products and approvals its business can continue growing sales by at least 4% per year until 2026.</p>\n<p>Currently, the stock trades at 20 times earnings. That's a deal given that the average healthcare stock in the <b>Health Care Select Sector SPDR Fund</b>&nbsp;trades at a multiple of more than 25. And Novartis' dividend yield of 3.8% makes the stock even more attractive to long-term investors. The average stock on the S&amp;P 500 pays a dividend that yields only 1.3%. I'm confident that as investors focus more on value next year, Novartis could become a more popular stock to own.</p>\n<h2>This monopoly is playing some new games</h2>\n<p><b>Keith Speights (Vertex Pharmaceuticals):</b> Vertex's share price dropped close to 25% year to date by early October. The biotech stock has since made a solid comeback, but it's still down 6%.</p>\n<p>The company has enjoyed a virtual monopoly in treating the underlying cause of cystic fibrosis (CF) for years. Vertex still has growth potential in the global CF market. However, investors have been anxious for the drugmaker to successfully expand into new therapeutic areas. Although Vertex has experienced some failures in the past with these efforts, it appears to be in a strong position to branch out beyond CF now.</p>\n<p>Vertex and <b>CRISPR Therapeutics</b> expect to file for regulatory approvals of CTX001 in late 2022. CTX001 is a promising CRISPR gene-editing therapy that could effectively cure transfusion-dependent beta-thalassemia and sickle cell disease.</p>\n<p>In addition to this partnered program, Vertex is advancing its internally developed candidate VX-147 into pivotal studies early next year targeting APOL1-mediated kidney disease. The company reported positive results from a phase 2 study evaluating the experimental drug earlier this month. Over 100,000 people in the U.S. and Europe have APOL1-mediated kidney disease. That's a bigger market than CF for Vertex to target.</p>\n<p>CTX001, VX-147, and continued momentum for the CF franchise are likely to be the primary growth drivers for Vertex in the near term. Over the longer term, though, the company could have additional winners from its pipeline. Vertex also has a hefty cash stockpile to use in making acquisitions and licensing deals.</p>\n<p>This has been a disappointing year for the big biotech stock. But&nbsp;I think 2022 will be a happy new year for Vertex shareholders.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks That Sank in 2021 but Could Soar in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks That Sank in 2021 but Could Soar in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 10:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/26/3-biotech-stocks-that-sank-in-2021-but-could-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no denying that 2021 has been a rough year for many biotech stocks. The shares of quite a few big and small biotech companies alike are set to finish the year in negative territory. But those ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/26/3-biotech-stocks-that-sank-in-2021-but-could-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc.","BK4567":"ESG概念","CF":"CF工业","BK4532":"文艺复兴科技持仓","BK4505":"高瓴资本持仓","NVS":"诺华","VERX":"Vertex, Inc.","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","VRTX":"福泰制药","BK4023":"应用软件","BK4007":"制药","BK4093":"化肥与农用药剂"},"source_url":"https://www.fool.com/investing/2021/12/26/3-biotech-stocks-that-sank-in-2021-but-could-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194177136","content_text":"There's no denying that 2021 has been a rough year for many biotech stocks. The shares of quite a few big and small biotech companies alike are set to finish the year in negative territory. But those disappointing performances won't necessarily extend into the future.\nWe asked three Motley Fool contributors to pick biotech stocks that sank in 2021 but could soar in 2022. Here's why they chose Axsome Therapeutics , Novartis , and Vertex Pharmaceuticals .\nLong-term catalysts abound for this biotech\nProsper Junior Bakiny (Axsome Therapeutics): Shares of Axsome Therapeutics have dropped by more than 50% this year. The company has had to deal with various setbacks. Most notably, the regulatory review of Axsome Therapeutics' lead pipeline candidate, AXS-05, was delayed. The Food and Drug Administration (FDA) was supposed to complete its review of the potential therapy for major depressive disorder in late August.\nBut the agency found deficiencies in Axsome Therapeutics' application. As a result, the FDA has yet to approve the drug. While this issue hurt Axsome Therapeutics' stock performance, the future looks bright for the company. AXS-05 proved effective at reducing the symptoms of depression in a late-stage study.\nThe need for a medicine like AXS-05 has only increased as a result of the pandemic, with the number of people suffering from symptoms of depression nearly quadrupling to 80 million since the outbreak started. AXS-05's delayed review isn't ideal, to say the least. But given the solid results it delivered in clinical trials and the dire need for depression therapies, it looks likely to hit the market eventually.\nBut Axsome Therapeutics is also developing several other medicines. These include AXS-07, a potential treatment for migraines, and AXS-12 and AXS-14, aimed at treating narcolepsy and fibromyalgia, respectively. The company estimates the potential annual sales of these medicines to be between $4 billion and $9 billion.\nMeanwhile, Axsome Therapeutics' market cap of $1.4 billion is currently less than half of the low end of these projections. That gives Axsome Therapeutics a tremendous upside potential. Naturally, risks are involved; the company could run into more regulatory roadblocks for AXS-05 or some other pipeline candidate.\nBut on the flip side, if Axsome Therapeutics starts racking up regulatory approvals for its therapies, its shares will soar next year and beyond. While I wouldn't recommend going all-in on this company -- it'd be best to initiate a small position, for now -- 2022 could prove to be a much better year for the biotech.\nReady to take off\nDavid Jagielski (Novartis): Investors have been moving away from high-priced growth stocks and into more value-oriented investments in recent weeks. One stock that has benefited from that is healthcare company Novartis, which is up over 5% in the past month while the S&P 500 has fallen 2%. The drugmaker's shares are still down 9% year to date. But if the shift to value stocks continues, Novartis may continue climbing into next year.\nThe business itself is in solid shape. Novartis posted a profit of $9.8 billion on sales of $52.4 billion over the trailing 12 months, good for a profit margin of just under 19%. It has also generated a boatload of money, with free cash flow during that time coming in at $12.2 billion. And the company is getting even more cash into its financials after selling its stake in drugmaker Roche for $20.7 billion. As a result of this windfall of cash, the company is planning to buy back up to $15 billion worth of its shares by the end of 2023.\nCash is king, and Novartis is generating plenty of it these days. That will give the company lots of flexibility moving forward should it want to pursue an acquisition or invest in expanding its business in other ways. Novartis projects that through new products and approvals its business can continue growing sales by at least 4% per year until 2026.\nCurrently, the stock trades at 20 times earnings. That's a deal given that the average healthcare stock in the Health Care Select Sector SPDR Fund trades at a multiple of more than 25. And Novartis' dividend yield of 3.8% makes the stock even more attractive to long-term investors. The average stock on the S&P 500 pays a dividend that yields only 1.3%. I'm confident that as investors focus more on value next year, Novartis could become a more popular stock to own.\nThis monopoly is playing some new games\nKeith Speights (Vertex Pharmaceuticals): Vertex's share price dropped close to 25% year to date by early October. The biotech stock has since made a solid comeback, but it's still down 6%.\nThe company has enjoyed a virtual monopoly in treating the underlying cause of cystic fibrosis (CF) for years. Vertex still has growth potential in the global CF market. However, investors have been anxious for the drugmaker to successfully expand into new therapeutic areas. Although Vertex has experienced some failures in the past with these efforts, it appears to be in a strong position to branch out beyond CF now.\nVertex and CRISPR Therapeutics expect to file for regulatory approvals of CTX001 in late 2022. CTX001 is a promising CRISPR gene-editing therapy that could effectively cure transfusion-dependent beta-thalassemia and sickle cell disease.\nIn addition to this partnered program, Vertex is advancing its internally developed candidate VX-147 into pivotal studies early next year targeting APOL1-mediated kidney disease. The company reported positive results from a phase 2 study evaluating the experimental drug earlier this month. Over 100,000 people in the U.S. and Europe have APOL1-mediated kidney disease. That's a bigger market than CF for Vertex to target.\nCTX001, VX-147, and continued momentum for the CF franchise are likely to be the primary growth drivers for Vertex in the near term. Over the longer term, though, the company could have additional winners from its pipeline. Vertex also has a hefty cash stockpile to use in making acquisitions and licensing deals.\nThis has been a disappointing year for the big biotech stock. But I think 2022 will be a happy new year for Vertex shareholders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164261351,"gmtCreate":1624208729873,"gmtModify":1703830685161,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Go","listText":"Go","text":"Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164261351","repostId":"2144775875","repostType":4,"repost":{"id":"2144775875","pubTimestamp":1624024260,"share":"https://ttm.financial/m/news/2144775875?lang=&edition=fundamental","pubTime":"2021-06-18 21:51","market":"us","language":"en","title":"Next Market Crash: 2 Top Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2144775875","media":"Motley Fool","summary":"Don't wait to jump on this red-hot tech company and unstoppable dividend stock.","content":"<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.</p>\n<p>No matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.</p>\n<h2>1. <a href=\"https://laohu8.com/S/FB\">Facebook</a></h2>\n<p><b>Facebook</b> (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.</p>\n<p>Facebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.</p>\n<p>2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.</p>\n<p>Facebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.</p>\n<p>If you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.</p>\n<p>After nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, <a href=\"https://laohu8.com/S/AONE\">one</a> that can generate consistent growth and maximize your portfolio returns.</p>\n<h2>2. AbbVie</h2>\n<p>Healthcare stock <b>AbbVie</b> (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from <b>Abbott Laboratories </b>in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.</p>\n<p>Stocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.</p>\n<p>The biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.</p>\n<p>There's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.</p>\n<p>Case in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.</p>\n<p>It's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.</p>\n<p>AbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.</p>\n<p>If you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Next Market Crash: 2 Top Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNext Market Crash: 2 Top Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144775875","content_text":"The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.\nNo matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.\n1. Facebook\nFacebook (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.\nFacebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.\n2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.\nFacebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.\nIf you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.\nAfter nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, one that can generate consistent growth and maximize your portfolio returns.\n2. AbbVie\nHealthcare stock AbbVie (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from Abbott Laboratories in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.\nStocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.\nThe biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.\nThere's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.\nCase in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.\nIt's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.\nAbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.\nIf you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.","news_type":1},"isVote":1,"tweetType":1,"viewCount":524,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374695247,"gmtCreate":1619443163689,"gmtModify":1704723930695,"author":{"id":"3567913702226999","authorId":"3567913702226999","name":"Someday","avatar":"https://static.tigerbbs.com/91b0144da7b9357384cef5bfff37ced7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567913702226999","authorIdStr":"3567913702226999"},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/374695247","repostId":"1186896771","repostType":2,"repost":{"id":"1186896771","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619442925,"share":"https://ttm.financial/m/news/1186896771?lang=&edition=fundamental","pubTime":"2021-04-26 21:15","market":"us","language":"en","title":"TSMC will invest $ 2.8 billion in China in order to increase chip production car","url":"https://stock-news.laohu8.com/highlight/detail?id=1186896771","media":"Tiger Newspress","summary":"TSMC will invest $ 2.8 billion in China in order to increase chip production car.","content":"<p>TSMC will invest $ 2.8 billion in China in order to increase chip production car.</p>\n<p><img src=\"https://static.tigerbbs.com/316b416c90dad568e492750f39e0aa30\" tg-width=\"840\" tg-height=\"470\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TSMC will invest $ 2.8 billion in China in order to increase chip production car</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTSMC will invest $ 2.8 billion in China in order to increase chip production car\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-26 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TSMC will invest $ 2.8 billion in China in order to increase chip production car.</p>\n<p><img src=\"https://static.tigerbbs.com/316b416c90dad568e492750f39e0aa30\" tg-width=\"840\" tg-height=\"470\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSM":"台积电"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186896771","content_text":"TSMC will invest $ 2.8 billion in China in order to increase chip production car.","news_type":1},"isVote":1,"tweetType":1,"viewCount":436,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}